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Abstract 
 
DNGR-1 is a C-type lectin receptor that has been implicated in the regulation of 
endocytic trafficking and cross-presentation of dead cell-associated antigens. Dendritic 
cells deficient in DNGR-1 are impaired in priming effector T-cell responses against 
cytopathic viruses and other dead cell-associated antigens. The ligand for DNGR-1 is 
the polymerized form of actin (F-actin) revealed in dead cells upon loss of membrane 
integrity. 
In this study we set out to determine biophysical, biochemical, and structural properties 
of DNGR-1 and its interaction with F-actin. 
First, we describe a conformational change that occurs in the neck region of the 
receptor in a pH- and ionic strength-dependent manner. Notably, the conformational 
change happens between conditions corresponding to the extracellular environment 
and the environment present in the vesicles of the endosomal pathway respectively, 
suggesting a possible role in the spatial regulation of the DNGR-1 function. 
Second, in collaboration with Keichii Namba and Takashi Fujii (RIKEN Quantitative 
Biology Center, Osaka, Japan) we used electron cryomicroscopy to solve the structure 
of DNGR-1 bound to F-actin at 7.7 Å resolution. Interestingly, DNGR-1 binds into the 
groove between actin protofilaments, making contacts with three actin subunits that are 
helically arranged in the F-actin structure. We identify the residues directly involved in 
the interaction, confirm their contribution to the binding and demonstrate the 
importance of avidity of the multivalent interaction between DNGR-1 and F-actin. 
Additionally, in collaboration with David Sancho and Salvador Iborra (Centro Nacional 
de Investigaciones Cardiovasculares, Madrid, Spain) we formally demonstrate that 
ligand recognition is prerequisite for the biological function of DNGR-1 in dendritic cells. 
Third, by using heterodimeric DNGR-1 proteins in which one half of the dimer is 
incapable of binding to ligand, we demonstrate that DNGR-1 can bind with both 
ligand-binding domains to a single actin filament, suggesting an exceptional flexibility of 
the neck region, and demonstrating an absence of rigid dimerization interface between 
the ligand-binding domains. 
In summary, we provide a comprehensive description of the structural and biophysical 
properties of DNGR-1, offering novel insights into its function and shedding light into 
innate immune mechanisms involved in recognition of cell death. 
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Chapter 1. Introduction 
1.1 Brief overview of the conceptual development of 
immunology 
Immune system is one of the basic mechanisms involved in the maintenance of 
homeostasis, and although some of its underlying features had been known for 
thousands of years, the beginning of the field of immunology as a science can be 
dated to the late 18th and early 19th century, and the experiments of Edward Jenner 
(Riedel, 2005). Like others before him, Jenner had noted that once recovered, 
cowpox patients appeared resistant to smallpox. Unlike his predecessors, however, 
Jenner set out to test the concept experimentally. By means of infecting a young 
boy with cowpox, followed by a challenge with smallpox, Jenner at the same time 
introduced the concept of vaccination and demonstrated the protection against 
smallpox infection, which eventually led to the eradication of the disease in the 20th 
century (Riedel, 2005). 
Jenner’s experiments, however, rested only on empirical findings and lacked all 
understanding of mechanisms underlying the observed phenomena. It was not until 
late 19th century that Robert Koch demonstrated the causal link between 
pathogenic microorganisms and human disease (Blevins and Bronze, 2010) and 
Elie Metchnikoff and Paul Ehrlich showed the involvement of phagocytes and 
antibodies, respectively, in their clearance (Gordon, 2008, Silverstein, 1999).  
The principal milestone in the development of the field of immunology as we 
understand it today only came in the second half of the 20th century with the 
formulation and development of the “self” and “non-self” hypothesis by MacFarlane 
Burnet and Peter Medawar, whereby they postulated that the immune system 
differentiates between endogenous and exogenous molecules, initiating a response 
against the latter, while maintaining tolerance to the former (Billingham et al., 1953, 
Burnet and Fenner, 1949).  
The last great conceptual leap in our understanding of the immune system came 
with the infectious non-self model originally proposed by Charles Janeway Jr. 
(Janeway, 1989). Building on the concept of antigen presenting cell (APC) 
introduced by Lafferty and Cunningham (Lafferty and Cunningham, 1975), 
Janeway suggested that APCs are able to recognize characteristic molecular 
Chapter 1 Introduction 
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patterns conserved between pathogens (PAMPs, pathogen-associated molecular 
patterns), thereby sensing infection, and in turn activate the adaptive immune 
system (Janeway, 1989). Abundant evidence in support of this model has 
accumulated over the last decades; however, certain phenomena such as 
transplant rejection, anti-tumour immunity or autoimmunity where no overt signs of 
infection could be detected still posed a conceptual problem. In attempt to explain 
these, danger theory was suggested by Polly Matzinger, according to which APCs 
could respond to specific endogenous signals released by stressed, damaged or 
dead cells (later termed DAMPs, damage-associated molecular patterns) 
(Matzinger, 1994).  
While controversies have arisen over the usefulness of the danger model, as well 
as over whether there can be a single “unifying theory” of how the immune system 
operates (Vance, 2000), clearly our understanding of the immune system has 
expanded explosively over the last decades, and the theories and models 
suggested previously have served us well thus far.  
 
1.2  Innate and adaptive immune system and their roles in 
homeostasis maintenance 
Historically, the immune system has been divided into two major parts – the innate 
and the adaptive. The innate immune system is evolutionarily older, appears to be 
present in some form in all animal and plant phyla, and its cells express only a 
limited set of germ line-encoded receptors specific for a limited set of molecules 
(Iwasaki and Medzhitov, 2015). The adaptive immune system, on the other hand, is 
generally considered to be present only in vertebrates and is characterised by the 
ability to somatically generate receptors of broad specificity, and by immunological 
memory (Hoffmann et al., 1999). It is getting increasingly clear, however, that albeit 
useful, this division is somewhat arbitrary (Borghesi and Milcarek, 2007), as certain 
subsets of B- and T-lymphocytes, the prototypical cells of the adaptive immune 
system, share multiple properties with innate cells (Bendelac et al., 2001), and 
certain innate cells show traits of the adaptive responses, such as memory-like 
activity reported in natural killer (NK) cells (O'Leary et al., 2006). Furthermore, 
certain features of “adaptivity” have been observed in organisms that are generally 
Chapter 1 Introduction 
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considered as having only the innate immune system, such as earthworms (Cooper, 
1968), freshwater snails (Zhang et al., 2004) or sea urchins (Rast et al., 2006), or 
as having no immune system at all, such as bacteria, and their newly-discovered 
ability to mount specific response to bacteriophages using the CRISPR Cas9 
system (Barrangou and Marraffini, 2014). Regardless of the exact definition, it is, 
however, still useful to think of the two systems in terms of their role and function in 
the maintenance of homeostasis.  
 
1.2.1 Innate immune system  
In the classical model, the cells and effector molecules of the innate immune 
system serve as the first line of defence against pathogens. Their responses are 
rapid to instantaneous, their ability to differentiate between self and non-self (or 
modified/missing self in the case of NK cells) is near absolute, and they can 
activate and instruct the adaptive immune system. On the other hand, barring 
certain exceptions, the innate immune system lacks the ability to generate diversity 
of receptor specificities, and immunological memory (Janeway and Medzhitov, 
2002).  
Low energy-cost and low threat-to-self potential combined with their fast mode of 
action make it possible for certain molecules of the first-line defences to be 
expressed and active constitutively (Iwasaki and Medzhitov, 2015). These include 
the antimicrobial peptides (AMPs) produced by many diverse tissues and cell types 
(Brogden, 2005), natural antibodies produced by the B1 cells (Schwartz-Albiez et 
al., 2009), or the serum complement system (Carroll, 2004), all of which are 
designed to clear the potential pathogen at minimal fitness cost to the host. If these 
turn out to be insufficient, cellular defences including cells of the 
polymorphonuclear and mononuclear phagocyte system as well as dendritic cells 
(DCs) placed at strategic sites throughout the body can be activated by microbial 
PAMPs, resulting in the phagocytosis of the invading pathogens as well as rapid 
production of cytokines and chemokines to activate and recruit other immune cells. 
Additionally, DCs migrate to lymphatic tissues such as lymph nodes and spleen 
and present microbial antigens to the adaptive immune system (Iwasaki and 
Medzhitov, 2015). Finally, at increased fitness cost, cells of the polymorphonuclear 
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system including neutrophils, basophils and eosinophils can be activated. Activated 
neutrophils in particular are extremely potent in clearance of extracellular 
pathogens, but at the same time their activation can result in significant collateral 
damage to the surrounding tissues due to release of reactive oxygen and nitrogen 
species (ROS and RNS) (Fialkow et al., 2007, Iwasaki and Medzhitov, 2015).  
In addition to the “classical” myeloid cells of the innate immune system mentioned 
above, innate lymphoid cells (ILCs) form a relatively newly recognised 
heterogeneous group of cells of the lymphoid lineage with diverse functions ranging 
from direct lysis of virus-infected or transformed cells to regulation of the 
development of lymphoid tissues to orchestrating the interplay between the 
immune system and commensal microbiota. It is becoming increasingly clear that, 
although rare, these cells play indispensable roles in the regulation of the immune 
system, and the field of ILC research is rapidly evolving (Walker et al., 2013). 
In sum, the function of the innate immune system is to hold off potential pathogens 
and where needed to activate and instruct the adaptive immune system (Iwasaki 
and Medzhitov, 2015). Based on the type of pathogen recognised and the cell 
initiating the response, different types of adaptive responses can be activated – 
cytotoxic T-lymphocytes (CTLs) and T helper type-1 (TH1) lymphocytes for 
elimination of intracellular pathogens, TH17 cells for elimination of extracellular 
bacteria and fungi, or TH2 cells for immunity against macroscopic parasites and 
venoms, underscoring the role of the innate immune system as the master 
controller of the immune response (Iwasaki and Medzhitov, 2015). 
 
1.2.2 Adaptive immune system 
In stark contrast to the innate immune system, the cells of the adaptive immune 
system are able to generate a diverse repertoire of antigen-specific receptors as 
well as immunological memory, allowing enhanced response towards the same 
antigen on the next encounter. The adaptive immune responses, however, take 
days to develop, for most part they need to be activated by the innate immune 
system, and the broad range of receptor-specificities brings about the risk of 
self-reactive clones (Boehm, 2011). 
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Traditionally T- and B-lymphocytes are considered the prototypical cells of the 
adaptive immune system, and in both cases they somatically generate diversity of 
their receptor-specificities by recombination-activating gene (RAG)-mediated 
rearrangement and recombination of genes coding for their T-cell receptors (TCRs) 
and B-cell receptors (BCRs) respectively (Fugmann et al., 2000, Tonegawa, 1983). 
This process results in generation of an immensely diverse anticipatory repertoire 
with, for example, up to 1015 possible canonical αβ TCR specificities predicted 
(Davis and Bjorkman, 1988). Of those, however, only a fraction gets expressed and, 
at least in the case of human, the lower limit has been estimated at 25 x 106 distinct 
TCRs in blood, although this might be an underestimate (Arstila et al., 1999, 
Nikolich-Zugich et al., 2004). Such a degree of diversity brings about a significant 
risk of self-reactivity, and consequently sophisticated mechanisms for elimination or 
functional inactivation of self-reactive clones have evolved, collectively termed 
central and peripheral tolerance (Nemazee et al., 2000, Piccirillo and Shevach, 
2004, Starr et al., 2003). 
In addition to the potential for autoreactivity, the high number of potential TCR and 
BCR specificities also means that of the several billion T- or B-cells present in the 
body, only several hundred are specific for any given antigen (Masopust and 
Schenkel, 2013). In order to mount an effective immune response, these are 
consequently the cells that need to be activated and rapidly expanded, while 
activation of all the other, non-cognate, cells is largely undesirable. This explains 
why it takes adaptive immune system significant amount of time to mount an 
effective response, but at the same time it brings to light an obvious conundrum of 
how the few antigen-specific cells are to find their cognate antigen in time 
(Masopust and Schenkel, 2013). As alluded to in the previous paragraphs, the 
innate immune system provides the solution to this problem in the form of the 
antigen presenting cells (APCs), the most prominent of which are the DCs. While 
lymphocytes circulate through lymphatic vessels and blood, APCs are stationed at 
strategic places throughout the body, and upon recognition of pathogens, they 
rapidly migrate to the nearest secondary lymphatic tissue – lymph nodes or spleen, 
where they can present the antigens to the lymphocytes that steadily circulate 
through these organs (Guermonprez et al., 2002, Masopust and Schenkel, 2013). 
After activation, T-cells undergo rapid proliferation, and based on their subtype, 
CD4+ T-cells become effector T helper cells (TH), specialised in production of 
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cytokines and helping other immune cells, while CD8+ T-cells become activated 
cytotoxic T-cells (CTLs) specialised in direct lysis of infected cells. After resolution 
of the infection and removal of the antigen, a “clonal contraction” phase ensues, 
when most of the T-cells undergo apoptosis, while a subset survives to become 
long-lasting memory T-cells. These cells exhibit remarkable heterogeneity with 
respect to their phenotype, localization, and functional potential, but they share the 
ability to rapidly respond to restimulation (Pulendran and Ahmed, 2006, Masopust 
and Schenkel, 2013). 
Unlike T-cells, B-cells can form germinal centres upon activation, and in addition to 
proliferation they undergo further rounds of genetic rearrangements, namely 
somatic hypermutation and class switch processes aimed at increasing the affinity 
of their BCRs for the presented antigens, and production of different classes of 
antibodies (Wagner and Neuberger, 1996). Germinal centre-selected B-cells then 
become short-lived antibody-producing cells, some of which have the potential to 
become long-lived plasma cells and constitutively produce lower amounts of 
antibodies for prolonged periods of time, or become long-lived memory B-cells, 
which, like their T-cell counterparts, are ready to be reactivated by next exposure to 
the same antigen (Radbruch et al., 2006). 
In sum, the adaptive immune system in the form briefly outlined above is an 
evolutionary novelty, present only in jawed vertebrates, and has evolved as an 
addition to the innate immune system. Given its mechanism of receptor specificity 
generation combined with its highly protective, but at the same time highly 
destructive potential, its activation and function needs to be tightly regulated. 
Taking into account both of the above, it is not surprising that the adaptive immune 
system is largely under control of the evolutionarily older, less error-prone innate 
immune system, and defects in any of the many regulatory mechanisms often 
result in immunopathologies including autoimmune diseases, allergies or 
immunodeficiencies (Milner and Holland, 2013, Waldner, 2009).   
 
1.3 Dendritic cells 
Dendritic cells were originally described by Steinman and Cohn in the spleen of 
mice based on their distinct morphology (Steinman and Cohn, 1973, Steinman and 
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Cohn, 1974). In the following decades, DCs were shown to be cells of the myeloid 
lineage, crucial for the initiation and regulation of adaptive immune responses, in 
particular due to their superior ability to present antigens and activate 
T-lymphocytes (Steinman and Idoyaga, 2010).  
The basis of the current, broadly accepted definition of DCs is their high expression 
level of integrin CD11c and major histocompatibility complex (MHC) class II 
molecules (Metlay et al., 1990, Nussenzweig et al., 1981) and their ability to prime 
T-cells (Heath and Carbone, 2009). This definition, however, is ambiguous, as 
other cell-types have been shown to express CD11c and MHC II, and even prime 
T-cell responses, making the definition of a DC context-dependent and open to 
multiple interpretations (Hume, 2008, Schraml and Reis e Sousa, 2015). This 
disparity has even led to suggestions that “DCs as a separate cell type with unique 
capacity or destiny do not actually exist” and that “they are simply a heterogeneous 
subset of mononuclear phagocytes” (Hume, 2008).  
Our current understanding of DC development is largely based on the mouse 
model, where a common precursor of both macrophage and DC lineages (MDP) 
has been defined (Fogg et al., 2006). MDP can further differentiate into a common 
DC precursor (CDP), which in turn can give rise to all DC subsets including 
plasmacytoid (pDC) and conventional (cDC) dendritic cells (Onai et al., 2007). 
Given this lineage specificity, it has been proposed that ontogeny-based definition 
of DCs rather than one based on phenotypical or functional properties should be 
used in order to resolve the ambiguity of DC definition (Guilliams et al., 2014, 
Schraml and Reis e Sousa, 2015). In this view, any cell derived from the CDP 
should be considered a DC, and conversely, no cell that derives from a different 
precursor should be called one, regardless of its functional or phenotypical 
properties (Guilliams et al., 2014). 
 
1.3.1 Function of dendritic cells 
DCs act as immunological sentinels, located throughout the body in an immature 
state (Stockwin et al., 2000). Upon recognition of PAMPs and certain DAMPs, DCs 
get activated and migrate from peripheral tissue where they encountered the 
pathogen into the secondary lymphoid tissues where they can in turn activate 
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T-cells. Upregulation of co-stimulatory molecules (CD80, CD86) together with MHC 
molecules, as well as production of cytokines are the characteristic hallmarks of an 
activated DC (Banchereau and Steinman, 1998). 
Exposure of DCs to PAMPs results in the production of many cytokines and 
chemokines, which serve to activate other innate immune cells including NK cells 
and neutrophils as well as to attract them to the sites of infection (Steinman and 
Hemmi, 2006). The main function of DCs, however, is presentation of antigens to 
T-lymphocytes, and this together with delivering the co-stimulatory signals results 
in activation of cognate T-cells and activation of the effector arm of the immune 
system (Hubo et al., 2013). In particular, DCs can present exogenous antigens on 
MHC class II molecules to CD4+ T-helper lymphocytes and, like any other cell, 
endogenous antigens on MHC class I molecules to CD8+ cytotoxic T lymphocytes 
(Blum et al., 2013, Steinman and Hemmi, 2006). 
The classical mode of presentation on MHC-I molecules involves predominantly 
26S proteasome-derived peptides of cytoplasmic proteins, which are translocated 
into the endoplasmic reticulum (ER) by the transporter associated with antigen 
processing (TAP) complex. Once inside the ER, the peptides can be loaded onto 
empty MHC-I molecules stabilised in a complex with tapasin, calreticulin and 
ERp57. Peptide binding then results in disassembly of the complex and export of 
the peptide-bound MHC-I to the cell membrane (Blum et al., 2013).  
MHC-II molecules are also assembled within the ER, together with the invariant 
chain. Invariant chain structurally stabilises the MHC-II molecule during the folding 
process, and prevents binding of ER-resident peptides. Functional maturation of 
MHC-II then takes place in an endosomal compartment, where the invariant chain 
is progressively degraded, leaving only a short peptide termed CLIP 
(class-II-associated invariant chain peptide) bound within the peptide-binding 
pocket. Finally, release of CLIP and binding of peptides derived from endocytosed 
proteins is mediated by MHC-related molecules DM and DO within late endosomes 
(Blum et al., 2013). 
In addition to the classical mode of MHC-I antigen presentation, exogenous 
antigens can also be presented on MHC-I in a process known as 
cross-presentation (Joffre et al., 2012). This pathway ensures that peptides derived 
from sources like viruses that do not infect DCs or from tumour cells can still be 
presented to cytotoxic T-lymphocytes (Zelenay and Reis e Sousa, 2013). In 
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principle the process of cross-presentation can be achieved in two ways – by 
endosome-to-cytosol translocation of endocytosed material followed by cytoplasmic 
degradation and loading of the peptides onto MHC-I in the classical pathway 
(Ackerman et al., 2006), or by means of direct loading of endocytosed 
material-derived peptides onto recycling MHC-I within the endocytic pathway (Shen 
et al., 2004). Of the two, the former appears to be more important (Rock and Shen, 
2005) and a molecular mechanism explaining the process of cytosol release 
through the translocon Sec61 has recently been reported (Zehner et al., 2015).  
Finally, as a counterpart to presentation of exogenous antigens on MHC-I, 
cytoplasmic and nuclear antigens can be presented on MHC-II through the process 
of autophagy, a mechanism useful for immunity against intracellular pathogens like 
viruses or certain bacteria (Crotzer and Blum, 2009). 
 
1.3.2 DC subsets and their roles within immune system 
DCs comprise of two major subsets – conventional DCs (cDCs) and plasmacytoid 
DCs (pDCs). pDCs significantly differ from the cDCs in that they express low levels 
of MHC-II and co-stimulatory molecules, and only a narrow range of pattern 
recognition receptors (PRRs). The characteristic PRRs include TLR 7 and 9, which 
allow pDCs to recognize foreign nucleic acids, to which they respond by strong 
production of type I interferons (IFNs). As such, pDCs are involved in anti-viral 
immunity (Reizis et al., 2011). 
cDCs can broadly be divided into lymphoid tissue-resident and migratory DCs. 
These can then be further subdivided based on their expression of integrin CD11b 
into CD11b+ and CD11b- DCs (Merad et al., 2013). CD11b+ DCs form a 
heterogeneous group of cells dependent on the transcription factor IRF4 in both 
lymphoid and non-lymphoid tissues (Suzuki et al., 2004). Lack of a specific model 
for CD11b+ DC depletion has made it difficult to assess the precise contribution of 
these cells (Merad et al., 2013), however, their superior expression of genes 
involved in MHC-II presentation suggests their involvement largely in activation of 
CD4+ T-helper cells (Dudziak et al., 2007). Recently the CD11b+ DCs were also 
shown to play an important role in T follicular helper (Tfh) cell induction, resulting in 
generation of humoural immune responses (Shin et al., 2015). 
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The CD11b- group of DCs is often referred to as “CD8α+-like” DCs and is 
characteristic by its CD8α expression in lymphoid organs, and CD103 expression in 
the case of the DCs in the tissues (Merad et al., 2013). In both cases, the cells 
share their dependence on IRF8 and Batf family transcription factors, and the 
ability to cross-present exogenous antigens to cytotoxic T-cells (Miller et al., 2012). 
In addition, CD8α+-like DCs show increased potential to activate cytotoxic T-cells 
regardless of their ability to cross-present, mainly due to higher expression of 
genes related to MHC-I presentation (Dudziak et al., 2007) and production of IL-12 
(Hochrein et al., 2001) and IL-15 (Mattei et al., 2001), two cytokines involved in 
differentiation of CTLs. CD8α+-like DCs express high levels of DNGR-1 in mouse 
(Caminschi et al., 2008, Sancho et al., 2008), and this pattern of expression 
appears to be shared between mouse and human where DNGR-1 identifies DC 
subset equivalent to murine CD8α+ DCs (Poulin et al., 2010). The expression of 
XCR1 marker is also restricted to the CD8α+-like family of DCs across species, and 
consequently, these cells are now often called XCR1+ DCs (Vu Manh et al., 2015). 
 
1.4 PAMP and DAMP recognition 
As postulated by Janeway in 1989, in order for an immune response to be initiated, 
innate immune system needs to detect presence of pathogens (Janeway, 1989). 
Specific receptors aimed at recognising PAMPs, broadly termed pattern recognition 
receptors (PRRs) are consequently expressed by a diverse range of cells of both 
innate and adaptive immune system as well as epithelial and other cell types. 
PRRs allow these cells to screen their environment for the presence of pathogens, 
and ligation of different classes of PRRs expressed by different cell types can gives 
the immune system detailed information about what kind of pathogen it faces 
(Iwasaki and Medzhitov, 2015). 
In addition to pathogen recognition by PRRs, immune system can also sense 
damage. When cells die by necrosis, they lose their membrane integrity, and as a 
consequence, proteins that are normally sequestered in the cytoplasm become 
exposed to the extracellular milieu (Zelenay and Reis e Sousa, 2013). Similar 
situation can occur if cells undergo apoptosis in numbers exceeding the capacity of 
scavenger cells to take up the apoptotic cell corpses. If not phagocytosed in a 
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timely fashion, apoptotic cells undergo secondary necrosis, which also results in 
the release of their cytosol components into the extracellular milieu (Silva, 2010). 
Thus expression of DAMP receptors on immune cells enables the immune system 
to sense the presence of damaged cells or excessive cell death. Interestingly 
though, while PAMP recognition almost universally results in activation of the 
PRR-expressing cell, and is often on its own sufficient for induction of inflammatory 
responses, DAMP recognition is significantly less potent and often results in 
regulation of other cellular functions, such as antigen handling by APCs (Zelenay 
and Reis e Sousa, 2013). 
 
1.4.1 PRRs and PAMP recognition 
Both PRR and PAMP are somewhat loosely defined terms. Any conserved 
molecule of pathogen origin that can be directly recognised by the innate immune 
system is usually referred to as a PAMP, and at the same time any receptor that 
recognizes a PAMP is considered a PRR. Regardless of the above, however, 
PAMPs generally are conserved molecules, often shared between multiple 
pathogenic agents, but absent from host cells (Akira et al., 2006). Notable 
exception from this rule are the nucleic acids, which are shared between the 
pathogen and the host, and their recognition as PAMPs is compartment-specific – 
for example DNA is recognised as a PAMP in the cytoplasm, but not in the nucleus 
(Barber, 2011). As a rule, PAMPs in their physiological role are of vital importance 
for the pathogen and its ability to infect the host, and their loss or modification 
usually results in a significant decrease in virulence or viability, or is impossible 
altogether. As such, escape strategies, often seen in the context of adaptive 
immune responses are not common, and PAMP recognition by PRRs provides an 
unambiguous way of detecting presence of pathogens (Akira et al., 2006). 
PRRs constitute several major groups of proteins, most prominently the 
transmembrane Toll-like receptors (TLRs) and C-type lectin receptors (CLRs), and 
cytosolic NOD-like receptors (NLRs) and RIG-I-like receptors (RLRs). The 
expression of many of these genes is not restricted to the innate immune system, 
and some are expressed universally by most, if not all cell types (Takeuchi and 
Akira, 2010). 
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TLRs are probably the best-known group of PRRs (O'Neill et al., 2013). The 
founding member of the family, Toll, was originally described in Drosophila 
melanogaster as a gene involved in embryogenesis, and only later its importance 
for the fly’s immune response was also recognised (Lemaitre et al., 1996). In a 
triumph of comparative immunology, shortly thereafter its mammalian homologue, 
later classified as Toll-like receptor 4 (TLR-4), was cloned and shown to induce 
activation of the immune system in response to bacterial lipopolysaccharide (LPS) 
(Medzhitov et al., 1997, Poltorak et al., 1998). Since then, thirteen members of the 
TLR family have been described (TLR-1 – 13) and shown to reside on the plasma 
membrane (TLR-1, 2, 4, 5, 6, 11, 12) or in the endosomes (TLR-3, 7, 8, 9, 10 and 
13). Broad spectrum of PAMP ligands for various TLRs have been identified, 
ranging from bacterial cell-wall constituents, to viral nucleic acids, to bacterial 
ribosomal RNA (O'Neill et al., 2013). The signalling pathways induced by various 
members of the TLR family are largely shared, and most TLRs signal either 
through MyD88 or TIRAP adapters towards NF-κB activation, resulting in 
production of proinflammatory cytokines, or through TRIF or TRAM adapters 
towards IRF3 activation and resultant production of type I IFNs. Uniquely among 
TLRs, TLR4 appears to utilise both of these pathways (Akira and Takeda, 2004).  
CLRs form the second large group of trans-membrane PRRs, and they will be 
discussed in greater detail in the following sections. 
Of all the main groups of PRRs, the cytosolic RLR family is the smallest with only 
three members – RIG-I, MDA5 and LGP-2 – and also exhibits the narrowest range 
of ligand-specificities. Both RIG-I and MDA5 have been shown to primarily 
recognise viral RNAs, while LGP-2 appears to be an accessory protein modulating 
signalling by the other two, although its exact function is not yet entirely clear 
(Goubau et al., 2013). Ligation of both RIG-I and MDA-5 results in their 
oligomerization-induced activation and binding to mitochondrial adapter MAVS, in 
turn activating the NF-κB as well as IRF3 and IRF7 transcription factors (Goubau et 
al., 2013). 
Finally, NLRs constitute a diverse family of cytoplasmic proteins, which are often 
considered PRRs, even though many of them show no direct binding to any known 
PAMPs (Franchi et al., 2006). Twenty three NLR genes have so far identified in 
human and thirty four in mouse (Rathinam et al., 2012). Based on the type of their 
N-terminal domain, four groups are currently recognised – NLRA (acid domain-
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containing), NLRB (BIR domain-containing), NLRC (CARD domain-containing) and 
NLRP (pyrin domain-containing), with a single uncategorised NLRX protein with no 
homology to the N-terminal domains of all the other NLRs (Ting et al., 2008). NLRs 
can be activated by diverse stimuli ranging from cytosolic dsDNA (through 
recognition by AIM2 and IFI16) (Hornung and Latz, 2010) to bacterial flagellin 
(through recognition by NAIP 5 and 6) (Kofoed and Vance, 2011) to multitude of 
disparate entities including extracellular ATP, pore-forming toxins or various 
crystals (through incompletely understood NLRP3-mediated mechanism) (Latz, 
2010). Upon activation, the NLRs oligomerize through their NACHT domains, 
forming large multi-protein complexes termed inflammasomes. The main role of 
inflammasomes is activation of caspase-1 from its inactive precursor pro-caspase-1. 
Pro-caspase-1 molecules are recruited to the inflammasome via direct 
CARD-CARD interaction or through interaction with additional adapter proteins, 
resulting in their proximity-induced autoproteolytic activation (Martinon et al., 2002). 
Finally, active caspase-1 mediates cleavage of pro-IL-1β and pro-IL-18 to their 
biologically active forms and their release, as well as induction of proinflammatory 
cell death termed pyroptosis (Davis et al., 2011, Rathinam et al., 2012).  
 
1.4.2 DAMP recognition by innate immune receptors 
Under steady-state conditions, cell death within a multicellular organism is a highly 
regulated process allowing for turnover of cells within tissues as well as removal of 
excess or no longer required cells and physiological structures during development. 
Such organised modality of cell death is called apoptosis, and its hallmark is 
activation of a class of cysteine proteases called caspases, resulting in the 
cleavage of various cellular substrates and easily recognizable cellular morphology 
with plasma membrane blebbing and separation of cell fragments into apoptotic 
bodies (Elmore, 2007). Under normal conditions, the apoptotic cell corpses are 
disposed of quickly and efficiently by phagocytic cells, usually macrophages and 
immature DCs, but in some cases also by the neighbouring cells (Hochreiter-
Hufford and Ravichandran, 2013). Soluble mediators known as “find-me” signals, 
as well as surface molecules referred to as “eat-me” signals have been shown to 
direct phagocytes to apoptotic corpses and to help distinguish them from 
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surrounding healthy cells (Hochreiter-Hufford and Ravichandran, 2013). Importantly, 
apoptosis is an immunologically silent process, and phagocytosis of apoptotic cells 
can even dampen inflammation by induction of anti-inflammatory cytokine 
production including TGF-β and IL-10 in macrophages (Chung et al., 2007, Fadok 
et al., 1998). 
In direct contrast to the “tidy” and controlled apoptosis, stands necrosis, the 
prototypical lytic form of cell death characterised by loss of membrane integrity and 
efflux of cytoplasmic components into the extracellular milieu. Classically, physical 
or chemical insults as well as lytic virus replication can directly cause necrosis 
(Krysko et al., 2008). In addition to the uncontrolled necrosis, a controlled lytic form 
of cell death termed necroptosis can be induced, most prominently, by signalling 
through the “death receptors” (Guicciardi and Gores, 2009) but also by 
engagement of various PRRs (Han et al., 2011). Recruitment of RIPK1 and RIPK3 
together with inhibition, often mediated by viral inhibitors, of apoptosis-inducing 
caspase-8, is essential for necroptosis induction (Moriwaki and Chan, 2013).  
Death by necrosis, necroptosis, or pyroptosis all result in the release of DAMPs 
(Kaczmarek et al., 2013). DAMPs themselves constitute a heterogeneous group of 
entities with no shared property other than their absence from extracellular milieu in 
steady state conditions (Table 1). Some of the DAMPs can be recognised by 
certain receptors that also function as PRRs mentioned in the previous section, 
while other DAMPs have dedicated, specific DAMP-receptors. In addition, 
surprising degree of promiscuity exists, and in many cases, one DAMP can be 
recognised by multiple DAMP-receptors, while one DAMP-receptor can often bind 
multiple DAMPs (Table 1) (Zelenay and Reis e Sousa, 2013). The fact that some 
DAMPs and PAMPs bind to the same receptors could suggest that the mode of 
action of, at least, certain DAMPs is equivalent to that of PAMPs, i.e. induction of 
inflammatory responses. Surprisingly though, this does not appear to be the case, 
and consequently, extra regulatory mechanisms must exist, allowing the 
differentiation between PAMP and DAMP recognition (Liu et al., 2009). For 
example, as mentioned in the previous section, TLR-4-mediated recognition of LPS 
leads to a potent NF-κB activation (Medzhitov et al., 1997, Poltorak et al., 1998). 
On the other hand, HMGB1 (Andersson and Tracey, 2011) or heat shock protein 
(HSP) (Quintana and Cohen, 2005) recognition by the same receptor is 
accompanied by the ligation of CD24, which in turn activates Siglec G (mouse) or 
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Siglec 10 (human), bringing activated phosphatases to close proximity of TLR-4 
and dampening the response (Liu et al., 2009). Consequently, it remains to be 
conclusively established whether the DAMP-induced responses are, at least in 
some cases, identical to those induced by PAMPs (Zelenay and Reis e Sousa, 
2013). 
 
DAMP Receptor Reference 
ATP P2X7 (Jarvis and Khakh, 2009) 
β-amyloid CD36, TLR-4, TLR-6, 
RAGE, NLRP3  
(Stewart et al., 2010), (Yan et al., 
1996), (Halle et al., 2008) 
Biglycan TLR-2, TLR-4 (Schaefer et al., 2005) 
Calreticulin CD91 (Obeid et al., 2007) 
DNA TLR-9, AIM2 (Boule et al., 2004), (Hornung et al., 
2009) 
Granulysin TLR-4 (Tewary et al., 2010) 
Heparan 
sulfate 
TLR-4 (Johnson et al., 2002) 
HMGB-1 TLR-4, CD24, RAGE (Andersson and Tracey, 2011), (Liu et 
al., 2009) 
HMGN-1 TLR-4 (Yang et al., 2012) 
HSPs TLR-2, TLR-4, CD24, 
CD14 
(Vabulas et al., 2001), (Fang et al., 
2011), (Liu et al., 2009), (Kol et al., 
2000) 
Hyaluronan TLR-2, TLR-4 (Jiang et al., 2005) 
H2O2 Lyn (Yoo et al., 2011) 
IL-1α IL-1R (Eigenbrod et al., 2008) 
IL-33 ST2 (Bonilla et al., 2012) 
RNA TLR-7, TLR-8 (Vollmer et al., 2005) 
SAP130 Mincle (Yamasaki et al., 2008) 
S100 RAGE (Hofmann et al., 1999) 
Table 1 Examples of previously described DAMPs and their receptors 
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1.5 C-type lectin receptors 
1.5.1 C-type lectin terminology 
Historically, lectins were defined as carbohydrate-binding proteins, and currently 
they are divided into at least twelve large, structurally distinct groups, of which the 
C-type and S-type lectins are the largest (Kilpatrick, 2002). C-type lectins can then 
be further divided into seventeen groups (I – XVII) based on their structure and 
phylogeny (Zelensky and Gready, 2005).  
C-type lectins were originally described as extracellular, Ca2+-dependent 
carbohydrate binding proteins structurally similar to the asialoglycoprotein receptor 
(Drickamer, 1988). The structural unit responsible for carbohydrate binding was 
termed carbohydrate recognition domain (CRD) and was shown to be conserved 
among members of the C-type lectin family (Drickamer, 1989). As new members of 
the family were described, however, it became clear that not all C-type 
CRD-containing proteins bind carbohydrates, or even Ca2+, and so in order to 
resolve the inconsistency, the term C-type lectin-like domain (CTLD) was 
introduced (Drickamer, 1999). Somewhat confusingly, the term now tends to be 
used interchangeably to describe either the whole group of domains with similarity 
to the C-type CRD regardless of their ability to bind carbohydrates, or as a term 
complementary to CRD, describing domains related to it but lacking 
carbohydrate-binding capacity (Zelensky and Gready, 2005).  
 
1.5.2 Structural features of C-type lectins 
The CTLDs of C-type lectins share a highly conserved fold consisting of two 
anti-parallel β-sheets and two α-helices (Figure 1.1). Typically, the β2 strand 
divides the structure into two lobes, the lower and the upper. The upper lobe is 
formed by the long loop region (LLR) and a β-sheet consisting of β2, β3 and β4 
strands, while the lower lobe contains both α-helices and a vertical β-sheet 
consisting of β1, β5 and β1’ strands (Zelensky and Gready, 2003). The presence of 
LLR further divides CTLDs into two large families – the canonical and the compact, 
of which the latter lacks the LLR. The LLR is classically involved in Ca2+-mediated 
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carbohydrate binding, even though some CTLDs of the compact family can still 
bind carbohydrates in Ca2+-independent manner (Zelensky and Gready, 2003). 
 
Figure 1.1 Structure of a prototypical CTLD from rat mannose binding protein A 
Structure of mannose binding protein (MBP) CTLD (PDB ID 1KWT)(Ng et al., 2002) 
as a prototypical C-type lectin with elements of secondary structure discussed in 
the text highlighted (α1, α2 and β1-β5). Green balls with green numbers 
correspond to Ca2+-binding sites occupied with Ca2+ ions and green circle 
corresponds to site 4, which is not occupied in MBP. C1 – C4 mark conserved 
cysteines forming intramolecular disulphide bonds. LLR = long loop region. 
 
The typical CTLD fold is stabilised by at least two disulphide bonds formed by four 
cysteines, which are also the most conserved CTLD residues, present in virtually 
all members of the C-type lectin family. C1 and C4 connect β5 and α1, helping 
stabilise the characteristic end-to-end structure where the C- and N-termini come 
into close proximity, and C2 and C3 link β3 and β5, providing stabilization to the 
upper part of the CTLD (Fig 1.1)(Drickamer and Dodd, 1999, Zelensky and Gready, 
2003, Zelensky and Gready, 2005). In addition, four other disulphide bonds have 
been described in various CTLDs, providing further stabilization of the structure 
(Drickamer and Dodd, 1999). 
Four Ca2+-binding sites appear within the CTLD fold, and their occupancy depends 
on the identity of the CTLD as well as on the crystallization conditions (Weis et al., 
1992, Weis et al., 1991). Of the four sites, three (1 – 3) are located in the upper 
lobe of the CTLD structure and one (4) between α2 helix and β1/5 sheet (Fig 1.1). 
Ca2+-binding residues within site 2 as well as the ion itself are involved in 
carbohydrate binding, while none of the other sites have been shown to play a role 
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in ligand recognition, and their function appears to be purely structural (Zelensky 
and Gready, 2005). Within site 2, a central role in carbohydrate binding is mediated 
by a conserved proline residue, the flanking residues of which dictate specificity of 
carbohydrate recognition – amino acid sequence EPN confers specificity for 
mannose, while QPD sequence is responsible for specificity for galactose. 
Consistently, switching motifs is enough, for example, to change the specificity of 
mannose binding protein A to galactose (Drickamer, 1992). 
As mentioned previously, not all members of the C-type lectin superfamily bind 
carbohydrates, and CTLDs have been described that bind proteins (Natarajan et al., 
2002), lipids (Sano et al., 1998) as well as inorganic compounds (Geider et al., 
1996). Unlike in the case of carbohydrate recognition, however, no conserved 
motifs responsible for the non-carbohydrate specificity have been described. 
 
1.5.3 C-type lectins in the immune system 
C-type lectins are divided into seventeen groups (I – XVII) of which at least six (II, 
III, IV, V, VI and XII) include proteins that play various roles in the immune system 
(Zelensky and Gready, 2005). Notably, group II includes receptors expressed by 
myeloid cells of both DC and macrophage lineage such as DC-SIGN and 
DC-SIGNR (Park et al., 2001), Mincle (Matsumoto et al., 1999), DCIR (Bates et al., 
1999) or MCL (Balch et al., 1998). Structurally its members are type II 
transmembrane proteins containing a short cytoplasmic tail, single carbohydrate 
and Ca2+-binding CTLD, and a neck region involved in oligomerization of the 
receptors (Sancho and Reis e Sousa, 2012, Zelensky and Gready, 2005).  
Group III, also known as collectins, includes serum mannose-binding proteins 
(MBPs) and pulmonary surfactant proteins (PSPs) involved in recognition of 
carbohydrate PAMPs and complement activation as well as activation of 
phagocytosis (Wright, 2004, van de Wetering et al., 2004). Characteristic 
organization of CTLDs into oligomeric complexes helps collectins recognise 
ordered arrays of carbohydrates, such as on the surface of pathogens (Zelensky 
and Gready, 2005).  
Members of group IV, collectively known as selectins, play crucial roles in cell 
migration and recruitment of immune cells to the sites of inflammation by mediating 
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both their initial attachment as well as the subsequent rolling movement. 
Universally, selectins bind carbohydrate sialyl LewisX moiety with low affinity, and 
additionally, different high-affinity glycoprotein ligands were identified for different 
members of the family (Somers et al., 2000).  
Group V, also known as NK-cell receptors includes several large receptor families 
including Ly49 (Anderson et al., 2001), NKG2 (Gunturi et al., 2004) and NKrp1 
(Plougastel and Yokoyama, 2006) as well as the Dectin family and CLEC2 (Sancho 
and Reis e Sousa, 2012). Most of the proteins are expressed on NK cells but some 
also on T-cells (Voehringer et al., 2002) and cells of the myeloid lineage (Tian et al., 
2005, Sancho and Reis e Sousa, 2012). The proteins are mostly dimeric, and bind 
protein ligands (Zelensky and Gready, 2005), although in some cases binding to 
carbohydrates has been described. Most prominent example of the latter is Dectin-
1, binding of which is Ca2+-independent, and involves an atypical carbohydrate-
recognition site (Adachi et al., 2004, Brown, 2006). 
Group VI is characteristic by its members expressing multiple CTLDs, and includes 
macrophage mannose receptor (MManR) and DEC205 (East and Isacke, 2002). 
Oligomeric nature of the proteins results in a high-affinity binding of polymeric 
ligands, even though most members of the group lack the residues involved in 
Ca2+-binding site 2 (Zelensky and Gready, 2005). 
Finally, group XII has a single member, eosinophil major basic protein (EMBP), 
which functions as a cytotoxic agent against macroscopic parasites. Its 
ligand-binding function is currently unclear, although binding to heparin has been 
reported (Swaminathan et al., 2001).  
 
1.5.4 Signalling by C-type lectins 
C-type lectins, like most other transmembrane receptors utilise conserved motifs to 
translate ligand recognition into a functional output. Based on the outcome of their 
signalling and the type of cytoplasmic signalling motifs, C-type lectins can be 
divided into four large groups: ITAM-coupled, ITIM-containing, hemITAM-containing 
and ITAM/ITIM-independent (Fig 1.2) (Sancho and Reis e Sousa, 2012). 
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Figure 1.2 Schematic depiction of C-type lectins and their signalling motifs 
Sequences of conserved signalling motifs are in white; tyrosine residues amenable 
to phosphorylation are highlighted in red. Charged residues mediating interaction 
between ITAM-bearing adapter and ITAM-coupled receptor are depicted as red 
circles with their charges in white. 
 
ITIM (immunoreceptor tyrosine-based inhibitory motif) containing receptors are 
characterised by the intracellular sequence (I/L/V/S)xYxx(L/V), which upon tyrosine 
phosphorylation allows recruitment of SH2 domain-containing phosphatases 
(SHP-1, SHIP, and in some cases also SHP-2) (Billadeau and Leibson, 2002). 
When activated by Src family kinases, the phosphatases can directly reverse 
activatory phosphorylation of other proteins (SHP-1/2) (Binstadt et al., 1996) or 
catalyse hydrolysis of membrane phosphoinositide triphosphate (SHIP), facilitating 
release of pleckstrin homology domain-containing proteins from the membrane, in 
turn blocking influx of extracellular calcium (Ravetch and Lanier, 2000).   
Unlike the ITIM, which is an integral part of the cytoplasmic domain of the receptors, 
the ITAM (immunoreceptor tyrosine-based activation motif), characterised by the 
YxxL/I(x6-8)YxxL/I sequence, is not expressed as a constituent part of C-type lectin 
receptors. Consequently, in order to signal through ITAM, the receptors need to be 
able to associate with ITAM-containing adapter proteins such as DAP12 or FcRγ 
(Billadeau and Leibson, 2002, Sancho and Reis e Sousa, 2012). The interaction is 
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mediated by charged residues within the transmembrane regions of both molecules 
– aspartate in the adapter protein and a conserved basic residue (arginine or 
lysine) in the receptor (Feng et al., 2005). Phosphorylation of both tyrosine residues 
within the ITAM of the adapter protein by Src family kinases then leads to 
recruitment of tandem SH2 domain-containing spleen tyrosine kinase (Syk), which 
in turn results in its autophosphorylation-mediated activation, and consequent 
induction of the downstream pathways including NF-κB, NFAT and others 
(Billadeau and Leibson, 2002, Sancho and Reis e Sousa, 2012, Mocsai et al., 
2010). 
As the name suggests, the hemITAM motif contains a single tyrosine residue within 
an YxxL motif, hence forming a “half” of the consensus ITAM. Unlike ITAM, 
hemITAM motifs are a part of the cytoplasmic domain of receptors (Rogers et al., 
2005). Like the full ITAM, however, hemITAM phosphorylation also creates a 
docking site for Syk recruitment, which results in its activation (Sancho and Reis e 
Sousa, 2012, Rogers et al., 2005, Kerrigan and Brown, 2010). It is currently not 
entirely clear how does single tyrosin-containing hemITAM motif support 
recruitment of the two SH2 domains of Syk, but it has been speculated that dimeric 
status of the hemITAM-bearing receptors can make the two hemITAMs serve as 
one “complete” ITAM (Sancho and Reis e Sousa, 2012, Kerrigan and Brown, 2010, 
Hughes et al., 2010). It remains to be established whether the modes of Syk 
activation by ITAM and hemITAM motifs are equal, but at least in the case of 
platelets this does not appear to be the case, as Syk activation by 
hemITAM-containing receptor CLEC-2 and ITAM-coupled receptor GPVI resulted 
in distinct functional outcomes (Manne et al., 2015). Whether this is a direct result 
of differential mode of Syk recruitment or if other mechanisms and molecules are 
involved will, however, need to be confirmed. 
The “ITAM/ITIM-independent receptors” is an umbrella term under which many of 
the receptors not fitting into any of the previous categories are grouped. As such, 
they have little in common apart from the fact that they can serve as endocytic 
receptors, and some have the potential to modulate signalling of other receptors, 
even though their stimulation alone does not result in any signs of cell activation. 
Examples include DEC205, LOX-1, langerin or CLEC-1 (Sancho and Reis e Sousa, 
2012). 
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1.5.5 HemITAM containing C-type lectins 
HemITAM containing C-type lectins form a small group of receptors with only four 
members: Dectin-1 (CLEC7A), CLEC-2 (CLEC1B), DNGR-1 (CLEC9A) and murine 
SIGNR3 (Sancho and Reis e Sousa, 2012, Kerrigan and Brown, 2010).  
Dectin-1 is often considered to be the prototypical example of hemITAM-bearing 
C-type lectins (Sancho and Reis e Sousa, 2012, Kerrigan and Brown, 2010, Brown, 
2006). It was originally described by subtractive cloning as a dendritic cell-
associated molecule (Ariizumi et al., 2000), and shortly thereafter it was identified 
to be the β-glucan receptor expressed by macrophages (Brown and Gordon, 2001). 
The expression pattern of Dectin-1 includes myeloid cells as well as a subset of γδ 
T-cells in mouse and also B-cells and eosinophils in human (Brown, 2006). As 
mentioned elsewhere, Dectin-1 binds carbohydrates through a Ca2+-independent 
mechanism (Adachi et al., 2004), however, the original report also suggested 
binding to an unidentified self-ligand on T-cells (Ariizumi et al., 2000). On the cell 
membrane, Dectin 1 is expressed as a monomer and binding to ligand is thought to 
induce its dimerization and translocation into lipid rafts, which in turn results in 
phagocytosis as well as NF-κB and NFAT activation (Goodridge et al., 2007, 
Hernanz-Falcon et al., 2009, Xu et al., 2009, Reid et al., 2009). NF-κB and NFAT 
are important proinflammatory programs in myeloid cells, and consequently, 
Dectin-1 signalling leads to production of cytokines including IL-2, IL-6, IL-10 and 
TNF-α as well as to DC maturation and subsequent activation of T-cells 
(LeibundGut-Landmann et al., 2007, Leibundgut-Landmann et al., 2008). 
Consistent with its activatory function and binding to β-1,3-linked glucans present in 
the cell wall of fungi and certain bacteria (Palma et al., 2006), Dectin-1 plays an 
important role in immunity against fungal pathogens, and Dectin-1-deficient mice 
showed impaired immune responses during fungal infection in vivo (Taylor et al., 
2007, Saijo et al., 2007).  
CLEC-2, the second hemITAM-containing receptor is expressed by multiple 
myeloid cell-types (Colonna et al., 2000) as well as by platelets (Suzuki-Inoue et al., 
2006) in both mouse and human. CLEC-2 is the target of snake venom rhodocytin, 
which activates CLEC-2, leading to Syk, Src, Tec and PLCγ2 activation and platelet 
aggregation. Additionally, an endogenous ligand for CLEC-2 exists – a cell-surface 
glycoprotein podoplanin (Suzuki-Inoue et al., 2006). Podoplanin-mediated 
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activation of CLEC-2 on DCs induces DC motility (Acton et al., 2012), while at the 
same time CLEC-2-mediated activation of podoplanin results in expansion of 
fibroblastic network within lymph nodes (Acton et al., 2014). Even though CLEC-2 
signals through Syk just as Dectin-1, its cross-linking results in NFAT but not NF-κB 
activation. Consequently, CLEC-2 signalling does not induce DC activation and 
only augments production of IL-2 and IL-10 when combined with TLR stimuli 
(Mourao-Sa et al., 2011). The reasons for this difference are not currently 
understood. 
Mouse SIGNR3 has an YxxL/I motif in the cytoplasmic domain just as its human 
homolog DC-SIGN, however only SIGNR3 has been shown to couple to Syk, and 
induce inflammatory cytokines in macrophages in response to mannosylated 
lipoarabinomannan, a component of Mycobacterium tuberculosis cell wall (Tanne 
et al., 2009). Human DC-SIGN does not couple to Syk, and consequently is not 
considered a hemITAM-containing receptor (Sancho and Reis e Sousa, 2012). 
Finally, DNGR-1 is the last example of hemITAM-containing C-type lectin receptors 
(Huysamen et al., 2008, Sancho et al., 2008) and will be discussed in greater detail 
in the following section. 
 
1.6 DNGR-1 
1.6.1 Discovery of DNGR-1 
DNGR-1 (DC, NK lectin group receptor 1), also known as CLEC9A or CD370 was 
independently reported by several groups (Caminschi et al., 2008, Huysamen et al., 
2008, Sancho et al., 2008) as a novel C-type lectin expressed on dendritic cells. 
While Sancho et al. and Caminschi et al. discovered DNGR-1 in screens designed 
to identify genes differentially expressed in different DC subsets (Caminschi et al., 
2008, Sancho et al., 2008), Huysamen et al. characterized it as a part of a 
systematic effort (Marshall et al., 2004, Huysamen et al., 2008) to analyse C-type 
lectins found in the NK gene complex, telomeric of CD94 (Sobanov et al., 2001). 
In both Sancho et al. and Huysamen et al. reports, DNGR-1 was shown to be a 
type II transmembrane protein with an intracellular signalling domain, and a single 
extracellular CTLD. In human, DNGR-1 is encoded by the Clec9a gene consisting 
of 6 exons with a single splice-variant (exons 1 – 6) described, while in the case of 
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the murine Clec9a gene seven exons were described (Huysamen et al., 2008, 
Sancho et al., 2008). Disparately, Sancho et al. number the murine exons 1 – 7, 
while Huysamen et al. refer to the fourth and fifth exon as exons 4’ and 4 
respectively. In all, five splice variants of murine DNGR-1 have been reported (Fig 
1.3). Sancho et al. describe three isoforms, which they term long (containing all 
seven exons), short (lacking exon 4) and very short (containing only exons 1 – 3 
and 7). In addition to these, Huysamen et al. describe two more isoforms – one 
lacking exon 2, and the other lacking exons 4 and 6 and containing a premature 
stop codon in exon 7 (Fig 1.3). For clarity, I will use the exon and splice variant 
notation as per Sancho et al. throughout. 
 
 
Figure 1.3 Schematic depiction of mouse DNGR-1 splice variants 
Each rectangle corresponds to one exon. Intracellular domain in yellow, 
transmembrane region in red, extracellular neck region in blue and CTLD in green. 
 
1.6.2 Genomic arrangement and isoforms of DNGR-1 
The genomic structure of DNGR-1 remains conserved between mouse and human, 
and in both cases exon 1 corresponds to a short cytoplasmic domain containing the 
hemITAM signalling motif, exon 2 to the transmembrane domain and exons 3 – 6 
or 7 in the case of the murine isoforms, to the extracellular domain composed of a 
C-type lectin-like domain (CTLD) and a membrane-proximal neck region (Fig 1.3). 
The neck region contains a conserved cysteine residue at position 94 (mouse) or 
96 (human), which is thought to be involved in covalent dimerization via formation 
of an intermolecular disulphide bond (Huysamen et al., 2008, Sancho et al., 2008). 
The CTLD of DNGR-1 contains six canonical cysteine residues stabilizing the 
CTLD fold by forming three disulphide bonds, but it lacks the conserved residues 
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involved in calcium coordination and carbohydrate binding (Huysamen et al., 2008, 
Sancho et al., 2008). 
The murine isoform that most closely resembles the human receptor is the short 
isoform. However, while human DNGR-1 (hDNGR-1) is expressed as glycosylated 
disulphide-bonded homodimer, the short mouse isoform was reported to be 
expressed as a non-glycosylated monomer (Huysamen et al., 2008). This 
observation appears counterintuitive, given that the long mouse isoform was 
reported to be a glycosylated, disulphide-bonded homodimer (Sancho et al., 2008), 
and the short isoform still contains the putative dimerization cysteine, as well as all 
the glycosylation sites, and also shows high degree of homology to the dimeric 
human variant.  
 
1.6.3 Structure of hDNGR-1 CTLD 
Crystal structure of glycosylation deficient S225D mutant CTLD of human DNGR-1 
was reported in 2012 (PDB ID 3VPP). It covers residues S111 – L236 with a 
stretch of five amino acids between E202 and N208 missing, presumably due to 
disordered nature of this region. A calcium ion involved in the formation of a salt 
bridge between α2 helix and β1/β5 sheet was observed coordinated within the 
structure (Fig 1.4) (Zhang et al., 2012), in the region corresponding to the calcium 
coordination site 4 as per Zelensky and Gready (Zelensky and Gready, 2005). This 
is consistent with the ion helping stabilize the fold of the CTLD, but not being 
involved in ligand binding (Zhang et al., 2012).  
In the crystal, the asymmetric unit contained a dimer of two CTLDs (Zhang et al., 
2012). The dimeric interface was, however, highly fenestrated and buried in it was 
a loop that is under normal conditions accessible to antibodies, suggesting that the 
interface was likely an artefact of crystal packing (Zhang et al., 2012). Structural 
homology of DNGR-1 to lectin-like oxidized low-density lipoprotein (LDL) receptor-1 
(LOX-1), also known as CLEC8A (PDB ID 1YPU, (Park et al., 2005)), led Zhang et 
al. to make a model of LOX-1-like dimer of DNGR-1 and to propose that the dimeric 
interface inferred from the model is more reflective of the form DNGR-1 takes 
under physiological conditions (Zhang et al., 2012). A subsequent study has, 
however, shown that a tryptophan residue in LOX-1 (W150), which is not 
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conserved between LOX-1 and DNGR-1, is crucial for maintaining the proper 
dimeric interface of LOX-1, and its loss results in abrogation of all inter-domain 
interactions between the two CTLDs even in the presence of the dimerization 
cysteine (Nakano et al., 2012). In light of these observations, the validity of the 
LOX-1-like model of DNGR-1 dimerization is questionable, and further work will be 
needed to confirm which form, if any, does the dimerization interface of DNGR-1 
take.  
 
Figure 1.4 Structure of hDNGR-1 CTLD 
Structure of hDNGR-1 CTLD (PDB ID 3VPP, (Zhang et al., 2012)) with the C- and 
N-termini as well as the missing region (dashed line) labelled. Ca2+ ion (green ball) 
and Ca2+-coordinating residues (sticks) are highlighted. 
 
1.6.4 DNGR-1 is involved in cross-presentation of dead cell-associated 
antigens 
The intracellular portion of DNGR-1 contains a hemITAM motif, which led to the 
assumption that DNGR-1 is an activatory receptor (Huysamen et al., 2008). 
DNGR-1 hemITAM bears resemblance to those of related C-type lectin receptors 
Dectin-1 and CLEC-2, both of which can serve as activatory receptors in DCs and 
platelets respectively (Sancho and Reis e Sousa, 2012). Antibody or 
ligand-mediated cross-linking of DNGR-1, however, did not lead to DC activation 
(Sancho et al., 2008), even though it could activate reporter cells co-expressing 
DNGR-1 and Syk (Sancho et al., 2009). The reasons for different ability of DNGR-1 
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to activate DCs and reporter cells are currently unclear, but can have to do with 
different levels of Syk expression or presence of other interacting molecules. 
Interestingly, the hemITAM of DNGR-1 differs from those of Dectin-1 and CLEC-2 
in that the DEDG sequence immediately upstream of the tyrosine, which was 
previously shown to be involved in signalling (Fuller et al., 2007) is substituted by 
AEEI or EEEI sequence in mouse and human DNGR-1 respectively (Fig 1.5) 
(Zelenay et al., 2012). This places a bulky hydrophobic isoleucine residue in the 
place where a small glycine is found in the other receptors, possibly creating a 
sterical hindrance that may result in a different mode of Syk recruitment and 
consequent attenuation of DNGR-1 signalling when compared with Dectin-1. In 
agreement with this notion, mutating the isoleucine to glycine improved the ability 
of DNGR-1 hemITAM to activate DCs upon ligand recognition in the context of 
chimeric receptors comprising the extracellular domain of Dectin-1 and intracellular 
domain of DNGR-1. Mutant generated by substituting the alanine present in murine 
isoform of DNGR-1 with aspartic acid on the other hand showed no phenotype 
(Zelenay et al., 2012). 
 
 
Figure 1.5 Alignment of DNGR-1, Clec2 and Dectin-1 intracellular domains 
Sequences of intracellular domains of human and mouse DNGR-1, Clec2 and 
Dectin-1 aligned using Clustal X software. Conserved DEDG motif is highlighted by 
red rectangle. 
 
DNGR-1 was shown to function as an endocytic receptor (Huysamen et al., 2008, 
Sancho et al., 2008) binding to a ligand revealed in cells that have lost their 
membrane integrity (Sancho et al., 2009). While DNGR-1 is not an activatory 
receptor, and its loss does not affect the ability of DCs to take up necrotic cell 
material, mice deficient in DNGR-1 (DNGR-1 KO) showed impairment in 
cross-presentation of dead cell-associated antigens. This resulted in a defect in 
activation of cytotoxic T-cell responses against model antigens carried by dead 
cells in a model of sterile immunity (Sancho et al., 2009). Subsequently, the 
phenotype was also extended to infection with viruses in vivo, where DNGR-1 KO 
Chapter 1 Introduction 
44 
 
animals showed weakened CTL responses to HSV-1 and Vaccinia viruses, as well 
as impairment in memory responses after vaccination (Iborra et al., 2012, Zelenay 
et al., 2012). 
 
1.6.5 DNGR-1 controls endocytic handling of dead cell-associated antigens 
Mechanistically, the ability of DNGR-1 to promote cross-presentation of dead 
cell-associated antigens is dependent on its interaction with Syk kinase, as 
Syk-deficient animals phenocopied DNGR-1-deficient ones (Sancho et al., 2009). 
The exact molecular mechanism of how DNGR-1 mediates cross-presentation 
remains elusive. However, DNGR-1 was shown to regulate intracellular trafficking 
of internalized material. In particular, DNGR-1 ligation led to targeting of dead 
cell-associated antigens to a non-degradative recycling endosomal compartment 
characterised by presence of Rab5 and Rab11 endosomal markers, while in 
DNGR-1-deficient cells the endocytic cargo was targeted to lysosomal 
compartment (Zelenay et al., 2012). Consistently, treatment with bafilomycin A1, an 
inhibitor of lysosomal acidification could restore the cross-presentation potential of 
DNGR-1 deficient DCs (Iborra et al., 2012), lending further support to the notion 
that the main function of DNGR-1 is to preserve the integrity of endocytosed dead 
cell-associated antigens. 
Taken together, these observations suggest a model where DNGR-1 affects 
handling of endocytic cargo through as-of-yet unknown mechanism, resulting in the 
inhibition of endosomal maturation and/or redirection of dead cell-associated 
material towards non-degradative endosomal compartments, and consequently 
increase in the amount of material available for cross-presentation (Fig 1.6). 
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Figure 1.6 DNGR-1 controls endocytic handling of dead cell-associated antigens 
Schematic depiction of the current model of DNGR-1 function in DCs, as described 
in the text. 
 
1.6.6 Identification of DNGR-1 ligand 
DNGR-1 was originally found to bind a ubiquitous intracellular molecule revealed in 
cells that have lost membrane integrity (Sancho et al., 2009). Further analysis 
showed that the ligand is predominantly cytoplasmic, resistant to nucleases and 
glycosidases, and susceptible to protease and acid treatment and heat 
denaturation (Sancho et al., 2009). Subsequently, the identity of the ligand was 
determined to be the filamentous form of actin (F-actin), while no binding was 
detected to the monomers of G-actin (Ahrens et al., 2012, Zhang et al., 2012). 
Actin is evolutionarily highly conserved, and consistent with that fact, human, turkey, 
trout, Drosophila and yeast F-actin could all be recognized by mouse DNGR-1 
(Ahrens et al., 2012).  
It was also suggested that the minimal requirement for DNGR-1 binding is actin in 
complex with calponin homology domain-containing actin-binding proteins (ABPs) 
such as β-spectrin and α-actinin (Zhang et al., 2012). Since F-actin depolymerizes 
under critical concentration of actin monomers, and this process can be delayed or 
reversed by presence of ABPs, filaments decorated with such proteins are more 
stable and possibly also more prone to form bundles, suggesting a plausible 
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explanation for the apparent increase in binding of DNGR-1 to such filaments 
(Ahrens et al., 2012).  
 
1.6.7 Cellular distribution of DNGR-1 
Among fully differentiated DC subsets in mouse, DNGR-1 expression is restricted 
to the CD8α+ and CD103+ CD11b- DCs, as well as, at lower levels, the 
plasmacytoid DCs (Caminschi et al., 2008, Poulin et al., 2012, Sancho et al., 2008). 
As such, high expression of DNGR-1 marks the cross-presenting, XCR-1+ DC 
subsets both in lymphoid and non-lymphoid tissues (Poulin et al., 2012). In human, 
none of the DC subsets express CD8α, which historically made it difficult to draw 
parallels between mouse and human. DNGR-1 expression on such cells, however, 
remains conserved between the two organisms, and consequently DNGR-1 
expression was shown to mark the human equivalent of mouse CD8α+ DCs (Poulin 
et al., 2012, Poulin et al., 2010).  
Notably, in mouse, DNGR-1 is also expressed at low levels on a DC precursor in 
both spleen and bone marrow (Schraml et al., 2013). Even though DNGR-1 
expression is subsequently lost in the CD11b+ DC subset, the history of DNGR-1 
expression can be used as a marker for the CDP progeny. Indeed, mice with Cre 
recombinase inserted into Clec9a locus were generated, and when crossed to 
Rosa26-stopflox yellow fluorescent protein (YFP) reporter mice, the resulting 
Clec9a+/cre Rosa+/EYFP animals could be used for lineage tracing and fate-mapping 
of cells derived from the CDP (Schraml et al., 2013). 
 
1.6.8 Antigen targeting to DNGR-1 promotes immune response 
CD8α+ DCs have been shown to potently cross-present exogenous antigens on 
MHC-I, and activate cytotoxic CD8+ T-cells (den Haan et al., 2000). The expression 
pattern of DNGR-1 makes it an interesting candidate for antigen delivery to 
CD8α+-like family of DCs (Sancho et al., 2008). Indeed, antibody targeting of 
antigens corresponding to tumour-derived peptides to DNGR-1 in the presence of 
adjuvants led to cytotoxic T-cell-mediated eradication of B16 melanoma lung 
pseudometastasis (Sancho et al., 2008).  
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In addition to CTL cross-priming, DCs can also activate CD4+ helper T-cells 
through antigen presentation on MHC-II, resulting in cellular as well as humoural 
responses. Hence, targeting of antigens to DNGR-1 does not only lead to 
MHC-I-mediated cross-presentation to cytotoxic T-cells, but also to 
MHC-II-mediated presentation to helper T-cells (Caminschi et al., 2008, Caminschi 
et al., 2012, Joffre et al., 2010). 
Multiple anti-DNGR-1 antibodies have been raised by different groups and utilised 
for antigen targeting to the receptor. Interestingly, different results were obtained 
with different antibodies, regarding the requirement (Joffre et al., 2010, Sancho et 
al., 2008), or not (Caminschi et al., 2008, Caminschi et al., 2012) for adjuvant co-
administration. In particular, targeting antigens to DNGR-1 with antibody clone 
7H11 required adjuvants to induce immunity. In their absence the induction of 
tolerance and generation of FoxP3+ regulatory T-cells was observed, while using 
different types of adjuvants resulted in different modality of T-helper cell responses 
– Poly I:C inducing TH1 response and curdlan inducing TH17 response (Joffre et al., 
2010). In contrast, antibody clone 10B4 was capable of inducing humoural 
responses towards antigen fused to it in an adjuvant-independent manner 
(Caminschi et al., 2008, Caminschi et al., 2012). In an attempt to reconcile these 
apparently conflicting data, a recent study (Li et al., 2015) compared side by side 
multiple anti-DNGR-1 antibodies, confirming the previously observed phenomena: 
treatment with 10B4 antibody resulted in efficient humoural response against the 
rat antibody in the absence of adjuvants, while 7H11 treatment resulted in efficient 
response only in the presence of adjuvants. The authors note that most properties 
of the two antibodies are comparable, however, the rat IgG2a heavy chain appears 
in general more immunogenic than IgG1κ (but not λ), suggesting that the difference 
between different DNGR-1 antibodies may be due to their different isotypes: 10B4 - 
IgG2a and 7H11 - IgG1 (Li et al., 2015).  
Targeting antigens to endocytic receptors expressed on DCs has shown promise in 
experimental as well as clinical settings (Steinman and Banchereau, 2007), and 
phase I and II clinical trials of vaccination are currently under way with 
antigen-coupled antibodies against DEC205, an uptake receptor expressed by DCs 
(Trumpfheller et al., 2012).  
Targeting DNGR-1 with antibodies in the murine model of vaccination resulted in 
potent induction of both cytotoxic (Sancho et al., 2008) and humoural (Caminschi et 
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al., 2008, Caminschi et al., 2012, Joffre et al., 2010) responses, suggesting 
possible usefulness of DNGR-1 for targeting of vaccines to DCs. Importantly, 
induction of humoral responses was also observed in non-human primate model 
with Macaca nemestrina monkeys even in the absence of adjuvants (Li et al., 2015). 
Important caveat, however, is that the antibody used in the macaque was the same 
rat IgG2a that elicited humoral responses in mouse without the need for adjuvants. 
Given that the potency of this antibody was likely at least in part due to its isotype 
(Li et al., 2015), it remains to be seen if DNGR-1 targeting would hold as much 
promise with humanised antibodies, which would need to be used should anti-
DNGR-1 antibodies ever be used in human medicine (Caminschi and Shortman, 
2012).  
 
1.7 Summary and objectives 
DNGR-1 is a C-type lectin receptor expressed by dendritic cells, involved in the 
cross-presentation of dead cell-associated antigens. While much is already known 
about its function and biology, certain critical questions still remain unanswered 
both at the level of its biochemical and structural properties, and at the level of its 
function in vivo.   
Consequently, in the following sections, I will attempt to provide answers to several 
of these questions, focusing on the biochemical and structural properties of the 
protein and its interaction with its ligand, F-actin, where possible drawing 
conclusions relevant for the biological function of the receptor, as well as 
highlighting some novel, previously unappreciated questions. 
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Chapter 2. Materials & Methods 
2.1 Reagents 
2.1.1 Buffers 
G-actin buffer: 5 mM Tris-HCl, pH 8.0 + 0.2 mM CaCl2 
F-actin buffer (10x): 100 mM Tris-HCl, pH 7.5 + 500 mM KCl + 20 mM MgCl2 + 
10 mM ATP 
Blocking buffer for Western blots and dot blots: 5% (w/v) milk in PBS + 
0.05% (v/v) Tween-20 
Interaction buffer for biolayer interferometry: F-buffer + 0.1% (w/v) BSA + 
0.02% (v/v) Tween-20 
Quenching buffer for biolayer interferometry: F-buffer + 0.1% (w/v) BSA + 
0.02% (v/v) Tween-20 + 10 µg/ml biocytin 
FACS buffer: 5 mM EDTA + 1% (v/v) FCS + 0.0125% (w/v) NaN3 in PBS 
CPRG 10x: 30 mM chlorophenol red-β-D-galactopyranoside (CPRG) in Z-buffer 
Z-buffer: 0.6 M Na2HPO4⋅7H2O + 0.4 M NaH2PO4⋅H2O + 0.1 M KCl + 0.01 M 
MgSO4⋅7H2O + 0.5 M β-mercaptoethanol 
CPRG lysis buffer: 1 x CPRG + 0.1% NP-40 + 10 mM MgCl2 in PBS 
PBS-based cell lysis buffer: 1% SDS in PBS 
Bis Tris-based cell lysis buffer: 1% SDS in 10 mM Bis Tris pH 5.5 
MES-based cell lysis buffer: 1% SDS in 10 mM MES pH 6.1 
6x Laemmli buffer: 12% SDS + 50% Glycerol + 60 mM Tris-HCl pH 6.8 + 
0.6 mg/ml bromophenol blue 
8 M Urea loading buffer: 8 M Urea + 2% SDS + 250 mM Tris-HCl pH 6.2 + 
0.001% bromophenol blue 
Buffers used for generating the 3D graph in Figure 3.3C: BisTris pH 6.5; PIPES 
pH 6.8; BES pH 7.1; MOPS pH 7.2; HEPES pH 7.5; Tricine pH 8.05, all 15 mM with 
addition of 0 – 250 mM NaCl 
 
Chapter 2 Materials and Methods 
 
50 
 
2.1.2 Proteins 
G-actin was bought lyophilised (Cytoskeleton), reconstituted in sterile water at the 
final concentration 10 mg/ml and stored at -80°C. Before use, the G-actin aliquots 
were diluted into G-actin buffer to final concentration 1 mg/ml and incubated for at 
least 30 minutes on ice.  
To polymerise G-actin into F-actin, 10x F-actin buffer was added to reconstituted 
G-actin (1 mg/ml), and the mixture was incubated for 1 hour at room temperature. 
Human platelet actin, biotinylated rabbit muscle actin, rabbit skeletal muscle 
α-actinin, and human recombinant plasma gelsolin were purchased from 
Cytoskeleton. 
DNGR-1 ECD proteins were generated by transient transfection of 293F cells.  
 
2.1.3 DNA 
Vector coding for long DNGR-1 ECD in CMV-9 backbone was prepared previously 
in the lab (Ahrens et al., 2012).   
Vectors coding for DNGR-1 or in pMSCV and pFB vectors were prepared 
previously in the lab (Sancho et al., 2009, Zelenay et al., 2012). 
DNA coding for human DNGR-1 isoform in pCDNA3.1 vector backbone was 
purchased from GenScript. 
 
2.1.4 Antibodies  
HRP-conjugated mouse anti-FLAG, clone M2 (Sigma Aldrich) 
HRP-conjugated rabbit anti-β-actin, clone 13E5 (Cell Signalling) 
HRP-conjugated rabbit anti-rat IgG (H+L), polyclonal (Jackson ImmunoResearch) 
purified rat anti-DNGR-1, clone 397 (Sancho et al., 2008) 
purified rat anti-DNGR-1, clone 7H11 (Sancho et al., 2008) 
PE-conjugated rat anti-DNGR-1, clone 1F6 (Sancho et al., 2008) 
Cy3-conjugated mouse anti-FLAG, clone M2 (Sigma Aldrich) 
M2-anti-FLAG affinity gel (Sigma Aldrich) 
anti-HA-Agarose, clone HA-7 (Sigma Aldrich) 
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2.1.5 Enzymes 
Calf intestinal phosphatase (New England Biolabs) 
Phusion High-Fidelity DNA polymerase (Thermo) 
PNGase F (New England Biolabs) 
Sortase A (kind gift from J. Huotari) 
T4 DNA ligase (New England Biolabs) 
 
2.1.6 Kits 
HiSpeed Plasmid Maxi Kit (Qiagen) 
QIAprep Spin Miniprep Kit (Qiagen) 
QIAquick Gel Extraction Kit (Qiagen) 
QIAquick PCR Purification Kit (Qiagen) 
QuikChange Lightning and Quick Change II XL Side-Directed Mutagenesis Kits 
(Agilent Technologies) 
 
2.2 Cloning 
2.2.1 Targeted mutagenesis of DNGR-1 constructs 
All mutations in all constructs were introduced using the QuikChange Lightning or 
QuikChange II XL kits with primer sequences shown in Table 2. All constructs were 
verified by sequencing. 
 
 
mutation 
direction 
of primer 
primer sequence (5’–3’) 
K57 – L66 
deletion 
fw CAAGGATGACGATGACAAGCTTGCGGCCGCGGAGCAGCAGGAAAGA
CTCATCCAACAGGAC 
rev GTCCTGTTGGATGAGTCTTTCCTGCTGCTCCGCGGCCGCAAGCTTGT
CATCGTCATCCTTG 
L64 – I73 
deletion 
fw CGGCCGCGAAGTTCTTCCAGGTATCCTCTCAACAGGACACAGCATTG
GTGAACCTTACAC 
rev GTGTAAGGTTCACCAATGCTGTGTCCTGTTGAGAGGATACCTGGAAG
AACTTCGCGGCCG 
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L72 – L82 
deletion 
fw CCTCTCTTGTCTTGGAGCAGCAGGAAAGAACACAGTGGCAGAGGAAA
TACACACTGGAATACTGCC 
rev GGCAGTATTCCAGTGTGTATTTCCTCTGCCACTGTGTTCTTTCCTGCT
GCTCCAAGACAAGAGAGG 
L72 – L82 
all Ala 
fw 
GGTATCCTCTCTTGTCTTGGAGCAGCAGGAAAGAGCCGCCGCCGCC
GCCGCCGCCGCCGCCGCCGCCACACAGTGGCAGAGGAAATACACA
CTGGAATACTGCCAAGCC 
rev 
GGCTTGGCAGTATTCCAGTGTGTATTTCCTCTGCCACTGTGTGGCGG
CGGCGGCGGCGGCGGCGGCGGCGGCGGCTCTTTCCTGCTGCTCCA
AGACAAGAGAGGATACC 
N81 – T90 
deletion 
fw GGAAAGACTCATCCAACAGGACACAGCATTGGTGCTGGAATACTGCC
AAGCCTTACTGCAGAGATCTCTCC 
rev GGAGAGATCTCTGCAGTAAGGCTTGGCAGTATTCCAGCACCAATGCT
GTGTCCTGTTGGATGAGTCTTTCC 
N81–T90 
all Ala 
fw 
GCAGGAAAGACTCATCCAACAGGACACAGCATTGGTGGCCGCCGCC
GCCGCCGCCGCCGCCGCCGCCCTGGAATACTGCCAAGCCTTACTGC
AGAG 
rev 
CTCTGCAGTAAGGCTTGGCAGTATTCCAGGGCGGCGGCGGCGGCG
GCGGCGGCGGCGGCCACCAATGCTGTGTCCTGTTGGATGAGTCTTT
CCTGC 
R87 – A96 
deletion 
fw GACACAGCATTGGTGAACCTTACACAGTGGCAGTTACTGCAGAGATC
TCTCCATTCAGGCAC 
rev GTGCCTGAATGGAGAGATCTCTGCAGTAACTGCCACTGTGTAAGGTT
CACCAATGCTGTGTC 
R87 – A96 
deletion 
+ Cys 
fw GACACAGCATTGGTGAACCTTACACAGTGGCAGTGCTTACTGCAGAG
ATCTCTCCATTCAGGCAC 
rev GTGCCTGAATGGAGAGATCTCTGCAGTAAGCACTGCCACTGTGTAAG
GTTCACCAATGCTGTGTC 
R87 – A96 
all Ala + Cys 
fw GACACAGCATTGGTGAACCTTACACAGTGGCAGGCCGCCGCCGCCG
CCGCCGCCTGCGCCGCCTTACTGCAGAGATCTCTCCATTCAGGCAC 
rev 
GTGCCTGAATGGAGAGATCTCTGCAGTAAGGCGGCGCAGGCGGCG
GCGGCGGCGGCGGCCTGCCACTGTGTAAGGTTCACCAATGCTGTGT
C 
Q95 – S104 
deletion 
fw CAGTGGCAGAGGAAATACACACTGGAATACTGCGGCACAGATGCTTC
TACTGGACCAG 
rev CTGGTCCAGTAGAAGCATCTGTGCCGCAGTATTCCAGTGTGTATTTC
CTCTGCCACTG 
Q95 – S104 
all Ala 
fw 
GTGAACCTTACACAGTGGCAGAGGAAATACACACTGGAATACTGCGC
CGCCGCCGCCGCCGCCGCCGCCGCCGCCGGCACAGATGCTTCTAC
TGGACCAGTTCTTCTGAC 
rev 
GTCAGAAGAACTGGTCCAGTAGAAGCATCTGTGCCGGCGGCGGCGG
CGGCGGCGGCGGCGGCGGCGCAGTATTCCAGTGTGTATTTCCTCTG
CCACTGTGTAAGGTTCAC 
C94S 
fw GGAAATACACGCTGGAATACAGCCAAGCCTTACTGCAGAGATC 
rev GATCTCTGCAGTAAGGCTTGGCTGTATTCCAGCGTGTATTTCC 
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H139A 
fw GACTGCAGCCCTTGTCCAGCCAACTGGATTCAGAATGG 
rev CCATTCTGAATCCAGTTGGCTGGACAAGGGCTGCAGTC 
H139N 
fw GACTGCAGCCCTTGTCCAAACAACTGGATTCAGAATGG 
rev CCATTCTGAATCCAGTTGTTTGGACAAGGGCTGCAGTC 
N140A 
fw GCAGCCCTTGTCCACACGCCTGGATTCAGAATGGAAAAAG 
rev CTTTTTCCATTCTGAATCCAGGCGTGTGGACAAGGGCTGC 
W141A 
fw GCAGCCCTTGTCCACACAACGCCATTCAGAATGGAAAAAGTTG 
rev CAACTTTTTCCATTCTGAATGGCGTTGTGTGGACAAGGGCTGC 
Y150A 
fw GATTCAGAATGGAAAAAGTTGTTACGCCGTCTTTGAACGCTGGGAAA
TGTGG 
rev CCACATTTCCCAGCGTTCAAAGACGGCGTAACAACTTTTTCCATTCTG
AATC 
E153A 
fw GGAAAAAGTTGTTACTATGTCTTTGCCCGCTGGGAAATGTGGAACAT
CAG 
rev CTGATGTTCCACATTTCCCAGCGGGCAAAGACATAGTAACAACTTTTT
CC 
W155A 
fw GTTGTTACTATGTCTTTGAACGCGCCGAAATGTGGAACATCAGTAAGA
AG 
rev CTTCTTACTGATGTTCCACATTTCGGCGCGTTCAAAGACATAGTAACA
AC 
K167A 
fw CATCAGTAAGAAGAGCTGTTTAGCCGAGGGCGCTAGTCTCTTTC 
rev GAAAGAGACTAGCGCCCTCGGCTAAACAGCTCTTCTTACTGATG 
E168A 
fw CATCAGTAAGAAGAGCTGTTTAAAAGCCGGCGCTAGTCTCTTTCAAAT
AGAC 
rev GTCTATTTGAAAGAGACTAGCGCCGGCTTTTAAACAGCTCTTCTTACT
GATG 
G188R 
fw GAAGAAATGGAGTTCATCAGCAGTATAAGGAAACTCAAAGGAGGAAA
TAAATATTGGG 
rev CCCAATATTTATTTCCTCCTTTGAGTTTCCTTATACTGCTGATGAACTC
CATTTCTTC 
K189A 
fw GGAGTTCATCAGCAGTATAGGGGCCCTCAAAGGAGGAAATAAATATT
GGG 
rev CCCAATATTTATTTCCTCCTTTGAGGGCCCCTATACTGCTGATGAACT
CC 
K191A 
fw CATCAGCAGTATAGGGAAACTCGCCGGAGGAAATAAATATTGGGTG 
rev CACCCAATATTTATTTCCTCCGGCGAGTTTCCCTATACTGCTGATG 
K189A 
K191A 
fw GGAGTTCATCAGCAGTATAGGGGCCCTCGCCGGAGGAAATAAATATT
GGG 
rev CCCAATATTTATTTCCTCCGGCGAGGGCCCCTATACTGCTGATGAAC
TCC 
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Table 2 Sequences of primers used for DNGR-1 mutagenesis 
 
K195D 
fw GGGAAACTCAAAGGAGGAAATGACTATTGGGTGGGAGTGTTTC 
rev GAAACACTCCCACCCAATAGTCATTTCCTCCTTTGAGTTTCCC 
E225A 
fw GACTTGTTGCCAGCAGCGAGACAGCGATCAGCCGGCC 
rev GGCCGGCTGATCGCTGTCTCGCTGCTGGCAACAAGTC 
R226A 
fw GACTTGTTGCCAGCAGAAGCGCAGCGATCAGCCGGCC 
rev GGCCGGCTGATCGCTGCGCTTCTGCTGGCAACAAGTC 
Q227A 
R228A 
fw GACTTGTTGCCAGCAGAAAGAGCCGCCTCAGCCGGCCAGATCTGTG
G 
rev CCACAGATCTGGCCGGCTGAGGCGGCTCTTTCTGCTGGCAACAAGT
C 
S229A 
fw GTTGCCAGCAGAAAGACAGCGAGCCGCCGGCCAGATCTGTGGATAC
C 
rev GGTATCCACAGATCTGGCCGGCGGCTCGCTGTCTTTCTGCTGGCAA
C 
Q232A 
fw GCAGAAAGACAGCGATCAGCCGGCGCCATCTGTGGATACCTCAAAG
ATTC 
rev GAATCTTTGAGGTATCCACAGATGGCGCCGGCTGATCGCTGTCTTTC
TGC 
K238A 
fw GGCCAGATCTGTGGATACCTCGCCGATTCTACTCTCATCTCAG 
rev CTGAGATGAGAGTAGAATCGGCGAGGTATCCACAGATCTGGCC 
D248A 
fw GATTCTACTCTCATCTCAGATAAGTGCGCCAGCTGGAAATATTTTATC
TGTGAG 
rev CTCACAGATAAAATATTTCCAGCTGGCGCACTTATCTGAGATGAGAGT
AGAATC 
W250A 
fw CATCTCAGATAAGTGCGATAGCGCCAAATATTTTATCTGTGAGAAGAA
GGC 
rev GCCTTCTTCTCACAGATAAAATATTTGGCGCTATCGCACTTATCTGAG
ATG 
K251A 
fw CTCAGATAAGTGCGATAGCTGGGCCTATTTTATCTGTGAGAAGAAGG 
rev CCTTCTTCTCACAGATAAAATAGGCCCAGCTATCGCACTTATCTGAG 
ΔLoop 
fw CTCTCTGACTTGTTGCCAGCAGCCGCCGCCGCCGCCGCCGCCGCCA
TCTGTGGATACCTCAAAGATTC 
rev GAATCTTTGAGGTATCCACAGATGGCGGCGGCGGCGGCGGCGGCG
GCTGCTGGCAACAAGTCAGAGAG 
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2.2.2 Expression vectors for short mouse and human DNGR-1 and Dectin 1 
ECD protein production 
Desired amplicons corresponding to the extracellular domains of short mouse and 
human DNGR-1 isoforms and mouse Dectin 1 were obtained using polymerase 
chain reaction (PCR) with Phusion High-Fidelity DNA polymerase, primers shown 
in Table 3 and template DNA in different vector backbones prepared previously by 
D. Sancho (unpublished), S. Zelenay (Zelenay et al., 2012) or purchased from 
GenScript respectively. PCR products were purified and digested with appropriate 
restriction endonucleases alongside empty CMV-9 vector backbone. Vector 
backbone was dephosphorylated by calf intestinal phosphatase treatment and both 
the digested amplicons and vector backbone were gel-purified by agarose gel 
electrophoresis. Purified backbone and amplicons were mixed and ligated with T4 
DNA ligase. All constructs were verified by sequencing. 
 
2.2.3 Generation of C9C7 chimeric receptors 
A “megaprimer” spanning the entire length of the neck region of long mouse 
DNGR-1 isoform with short sequences complementary to the regions upstream and 
downstream of the Dectin-1 neck region was generated using PCR with Phusion 
High-Fidelity DNA polymerase, primers shown in Table 3, and DNA template 
containing the sequence of entire DNGR-1. “Megaprimer” was agarose gel-purified 
and used in a modified site-directed mutagenesis reaction using QuikChange II XL 
site-directed mutagenesis kit as per manufacturer’s instructions. The constructs 
were verified by sequencing. 
 
2.2.4 Generation of CMV-9 vector for expression of HA-tagged proteins 
CMV-9 vector backbone contains sequence coding for 3xFLAG tag upstream of the 
sequence coding for the protein of interest. To replace the 3xFLAG-coding 
sequence with one coding for HA, QuikChange II XL mutagenesis kit and primers 
shown in Table 3 were used. The resulting construct was verified by sequencing. 
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2.2.5 Generation of sortagged DNGR-1 constucts 
Sortag together with His tag were introduced at the C-terminus of DNGR-1 in 
CMV-9 vector using QuikChange II XL mutagenesis kit and primers shown in Table 
3. The resulting constructs were verified by sequencing. 
 
 
construct 
direction 
of primer 
primer sequence (5’–3’) 
short mouse 
DNGR-1 ECD 
fw AAAAAACTCGAGGCCGCCGCCGCCATGCATGCGGAAGAAATA
TATACCTCTCTTCAGTGGG 
rev AAAAAAAAGCTTCAGATGCAGGATCCAAATGCTTTCTTCTCAC
AG 
human 
DNGR-1 ECD 
fw AATTGCGGCCGCGAAGTTGTTGCAGGTGTCCACCATTGCGAT
GC 
rev AATCTAGATCAGACAGAGGATCTCAACGCATACTTCTCACAG 
Dectin1 ECD 
fw AAAAAACTCGAGCCGCCATGAAATATCACTCTCATATAGAGAA
TCTGGATGAAGATGGATATACTC 
rev TTTTTTGCGGCCGCTCACAGTTCCTTCTCACAGATACTGTATG
AAGAAGTATTGCAG 
“megaprimer” 
for C9C7 
generation 
fw GCTGGGTGCCCTAGCATTTTGGAAGTTCTTCCAGGTATCCTCT
CTTG 
rev CCATGCATGATCCAATTAGGAAGGCATGTTTCCTTGCTGTCCA
GGGTCTG 
HA –tagged 
DNGR-1 
fw GCTCTTGTTGGAGCTGCAGTTGCTTACCCTTACGATGTGCCCG
ATTACGCCGCGGCCGCGAAGTTCTTCCAG 
rev CTGGAAGAACTTCGCGGCCGCGGCGTAATCGGGCACATCGT
AAGGGTAAGCAACTGCAGCTCCAACAAGAGC 
C-terminally 
sortagged 
DNGR-1 
fw GCATCCTACCGGAAACAGGGCATCATCACCATCACCACTGAT
CTAGAGGATCCCGGG 
rev CCCGGGATCCTCTAGATCAGTGGTGATGGTGATGATGCCCTG
TTTCCGGTAGGATGC 
Table 3 Sequences of primers used for generation of indicated constructs 
 
2.3 Cells 
Phoenix, B3Z-Syk (Sancho et al., 2009) and GP2-293 cells were grown in 
RPMI1640 medium supplemented with glutamine, penicillin, streptomycin, 
2-mercaptoethanol and 10% heat-inactivated foetal calf serum (FCS) at 37°C and 
5% CO2. 
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MuTuDC1940 (Fuertes Marraco et al., 2012) cells were grown in IMDM medium 
supplemented with 2-mercaptoethanol and 10% heat-inactivated foetal calf serum 
(FCS) at 37°C and 5% CO2. 
293F cells were grown in FreeStyle 293 Expression Medium at 37°C, 8% CO2 and 
constant shaking on an orbital shaker at 120 rpm. 
For Flt3 ligand DC cultures, bone marrow was flushed out of femurs and tibiae of 
mice of desired genotype, washed and seeded in a 6-well plate at 2 x 106 cells per 
well. The cells were cultured for 9 days in complete RPMI1640 medium additionally 
supplemented with 150 ng/ml recombinant Flt3 ligand. 
 
2.3.1 Transient transfections of 293F cells 
293F cells grown in 30 ml of medium in T-75 flasks were adjusted to density of 
1 x 106 per ml and transfected with a mixture of 60 µl 293fectin and 30 µg of DNA 
coding for the desired protein in CMV-9 backbone in 2 ml of Opti-MEM medium. 
 
2.3.2 Retroviral transductions 
70% confluent GP2-293 packaging cells in 10 cm dish were transfected with a 
mixture of 18 µl GeneJuice, 6 µg of VSV-G envelope protein-coding plasmid and 
6 µg of plasmid coding for the desired protein in pMSCV or pFB backbone in 600 µl 
of Opti-MEM medium. On days 1, 2 and 3 post-transfection, the pseudotyped 
virus-containing culture medium was replaced with fresh one, filtered through 
0.44 µm filter, supplemented with 8 µg/ml polybrene and immediately applied onto 
Phoenix cells grown in a 6-well plate format. The plate was centrifuged for 
90 minutes at 2500 x g at room temperature and left in the incubator for further 
90 minutes. After the incubation, the medium was exchanged for fresh complete 
RPMI1640 medium. On the third day, the Phoenix cells were re-plated into a 10 cm 
dish and expanded. 
For transduction of B3Z-Syk, MuTuDC1940 and Flt3L DCs, ecotropic 
virus-containing supernatant from Phoenix cells was used, and in case of Flt3L 
DCs protamine sulphate was used instead of polybrene. 
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2.4 Protein production and purification 
2.4.1 DNGR-1 ECD production in 293F cells 
All DNGR-1 extracellular domain (ECD) proteins (K57 – I264) were produced by 
transient transfection of 293F cells as described above. At 72 hours 
post-transfection, the cells were pelleted by centrifugation and the medium was 
collected and filtered through 0.22 µm filter to remove any cell debris. Supernatants 
were then either directly used for protein purification, stored at -80°C or used for 
experiments and stored for short times at 4°C. 
 
2.4.2 Protein purification 
Following protein production, the proteins were purified by combination of affinity 
and size exclusion chromatography. M2-anti-FLAG gel (Sigma) was stacked into a 
column according to manufacturer’s instructions and the protein supernatant was 
allowed to pass through by gravity flow. The flow-through was collected and 
passed through the column one more time. The column was washed with 15 
column volumes of PBS and the protein was eluted by 5 column volumes of PBS 
with 200 µg/ml of 3xFLAG peptide. Eluate was concentrated in centrifugation 
concentrators (Merck Millipore) to approximately 500 µl and purified using size 
exclusion chromatography on Superdex S200 column (GE Healthcare). Fractions 
corresponding to DNGR-1 peak were pooled and concentrated using centrifugation 
concentrators to approximately 1 mg/ml. Aliquots of concentrated DNGR-1 ECD 
were stored at -80°C and thawed directly before each experiment. 
 
2.4.3 Heterodimeric DNGR-1 ECD generation and purification 
293F cells were transfected with a mixture of constructs coding for the desired 
dimer parts (HA-W155A W250A ECD + FLAG-WT ECD or HA-WT ECD + 
FLAG-WT ECD) at 2:1 ratio of HA:FLAG, and the supernatant was harvested 3 
days later, filtered through 0.22 µm filter and allowed to pass through anti-HA 
agarose (Sigma) column by gravity flow. The column was washed with 15 column 
volumes of TBS buffer supplemented with 10 mM CaCl2, and the protein was 
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eluted with HA peptide (200 µg/ml, 5 column volumes) in TBS + CaCl2. The eluate 
(3ml) was used in sortagging reaction with 5 µM evolved sortase A and 5 µM 
AF647 peptide at room temperature for 1 hour. After the reaction, the mixture was 
allowed to pass through the anti-FLAG (Sigma) column by gravity flow, the column 
was washed with 5 column volumes of TBS, followed by 10 column volumes of 
PBS, and the protein was eluted with 5 column volumes of 3xFLAG peptide (200 
µg/ml) in PBS. 
 
2.5 Protein-based assays 
2.5.1 Densitometry of DNGR-1 proteins in culture supernatants 
Equal amounts of cell culture supernatants after DNGR-1 ECD production in 293F 
cells were analysed by SDS-PAGE and Western blot with HRP-conjugated 
anti-FLAG antibody used for detection. The signal of DNGR-1 bands was quantified 
using ImageJ software, and relative concentration of DNGR-1 proteins in the 
supernatants was determined as the ratio between signal of DNGR-1 mutant and 
WT. 
 
2.5.2 Dotblot for DNGR-1 mutants 
F-actin stabilised by 5 µM phalloidin was spotted onto a nitrocellulose membrane in 
twofold dilution starting at 40 µg/ml, 100 µl per spot. The membrane was blocked in 
5% milk in PBS + 0.05% Tween-20 overnight. Following day, the membrane was 
incubated with supernatants containing relevant proteins at equal concentration. 
Membrane was washed 5 times in PBS + 0.05% Tween-20, and incubated with 
HRP-conjugated anti-FLAG antibody in 5% milk in PBS + 0.05% Tween-20, 
washed 5 times in PBS + 0.05% Tween-20, and DNGR-1 binding was revealed 
using SuperSignal West Pico Chemiluminescent substrate. Signal in blots was 
quantified using ImageJ software and made relative to signal of WT.  
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2.5.3 Dotblot for DNGR-1 interaction with F-actin under different pH 
F-actin stabilised by 5 µM phalloidin was spotted onto a nitrocellulose membrane in 
twofold dilution starting at 40 µg/ml, 100 µl per spot. The membrane was blocked in 
5% milk in PBS + 0.05% Tween-20 overnight. Following day, the membrane strips 
were transferred into 3 ml of either PBS or MES pH 6.1 buffers and 3 µg of purified 
DNGR-1 ECD or 500 µl of protein supernatant was added for 1 hour. The 
membrane was washed 5 times in PBS + 0.05% Tween-20 or MES + 0.05% 
Tween-20, for half of the membrane strips, the buffers were swapped for the last 
wash, and the membrane was incubated for another hour with HRP-conjugated 
anti-FLAG antibody in PBS + 0.05% Tween-20 or MES + 0.05% Tween-20, 
washed 5 times in the corresponding buffer, and DNGR-1 binding was revealed 
using SuperSignal West Pico Chemiluminescent substrate. 
 
2.5.4 Pelleting assay 
2 µg of F-actin in 10 µl of F-buffer was mixed with decreasing amounts of DNGR-1 
ECD (WT or indicated mutant) in 30 µl of PBS, starting at 5 µg and decreasing in 
twofold dilution. As a control, 5 µg of DNGR-1 ECD was mixed with F-buffer only. 
Mixture was left for 1 hour at room temperature and pelleted at 120 000 x g for 
90 minutes. Both pellet and supernatant were analysed by SDS-PAGE and 
Western blot with HRP-anti-FLAG antibody. 
 
2.5.5 Biolayer interferometry with DNGR-1 in solution 
All biolayer interferometry (BLI) experiments were carried out using Octet RED96 
System (ForteBio). Streptavidin (SA) biosensors (ForteBio) were pre-wetted in 
water for 20 minutes and equilibrated in F-buffer for 30 s. Biotinylated and 
non-biotinylated G-actin were mixed in 1:4 ratio, diluted to final concentration of 
1 µM in 200 ml of F-buffer, and allowed to polymerize directly on the SA biosensors. 
Free binding sites on SA were blocked in the quenching buffer. Baseline was 
determined in the interaction buffer and association with DNGR-1 WT or mutants at 
different concentrations (2.5 µM, 1 µM, 0.4 µM, 0.167 µM and 0.064 µM) was 
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monitored for 300 s. Dissociation was monitored for 900 s. Data analysis was 
performed in Data Analysis 4.1 software (ForteBio). 
 
2.5.6 Biolayer interferometry with DNGR-1 on the sensor 
23 µM actin was polymerised in the presence of 0.23µM gelsolin to reduce the size 
of the resulting filaments, as large filaments caused artefacts in BLI signal. 
Anti-FLAG (FLG) biosensors (ForteBio) were pre-wetted in water for 20 minutes 
and equilibrated in PBS for 60 s. DNGR-1 ECD was diluted to 0.15 µM and allowed 
to bind to the sensor for 180 s. Baseline was established in the interaction buffer 
containing 5 µM phalloidin, and association with 1 µM short actin filaments was 
observed for 600 s in the interaction buffer. Dissociation was monitored for 900 s in 
the interaction buffer with 5 µM phalloidin to prevent depolymerisation of the 
filaments bound to DNGR-1. Data analysis was performed in Data Analysis 4.1 
software (ForteBio). 
 
2.5.7 Multi-angle light scattering 
Purified DNGR-1 ECD was concentrated to 4 mg/ml and immediately before the 
analysis, 200 µg of the protein was mixed 1:1 with PBS or 10 mM MES pH 6.1. 
Size exclusion chromatography was performed on Superdex S75 column, and 
MALS data were acquired on Dawn Heleos instrument (Wyatt).   
 
2.5.8 Far-UV circular dichroism 
Long mouse DNGR-1 ECD was concentrated to 7 mg/ml and immediately before 
analysis diluted into PBS or 10 mM MES pH 6.1 to final concentration 170 µg/ml. 
Human ECD was concentrated to 1.4 mg/ml and immediately before analysis 
diluted into PBS or 10 mM MES pH 6.1 to final concentration 140 µg/ml. 20 CD 
spectra per sample per condition were acquired in the region between 196 nm and 
260 nm and averaged to obtain final spectra. 
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2.5.9 Near-UV circular dichroism 
Long mouse DNGR-1 ECD was concentrated to 5 mg/ml and immediately before 
analysis diluted tenfold into PBS or 10 mM MES pH 6.1. 20 CD spectra per sample 
per condition were acquired in the region between 255 nm and 450 nm and 
averaged to obtain final spectra. 
 
2.6 Cellular assays 
2.6.1 Dead cell staining  
HeLa cells were UV-irradiated (UVC 240 mJ/cm2) and left to undergo secondary 
necrosis. Next day, the cells were washed in FACS buffer and stained with WT or 
mutant DNGR-1 ECD supernatants at equal concentration. The cells were washed 
in FACS buffer and binding of DNGR-1 was revealed using Cy3-anti FLAG 
antibody. Data were acquired on LSR Fortessa flow cytometer (BD Biosciences). 
To discriminate cells that had lost their membrane integrity, DAPI was added to 
each sample immediately before analysis. Data were analysed using FlowJo 9.6.2 
software (Treestar), and to quantify the binding, binding index was calculated as 
the mean fluorescence intensity of DNGR-1+ cells multiplied by their frequency in 
the DAPI+ population and normalized to WT.  
 
2.6.2 Internalization assay 
Phoenix cells expressing full length WT or mutant DNGR-1 proteins were treated 
with 1 µM F-actin, F-buffer only, 5 µg/ml anti-DNGR-1 antibody (clone 7H11) or 
isotype control antibody and incubated at 37°C for 1 hour. Following the incubation, 
the cells were washed in ice-cold PBS + 5 mM EDTA, stained with LIVE/DEAD 
Fixable Dead Cell Stain (Life Technologies) and fixed in 2% formaldehyde. Fixed 
cells were washed in FACS buffer and stained with PE-conjugated anti-DNGR-1 
antibody (clone 1F6). Data were acquired on LSR Fortessa flow cytometer (BD 
Biosciences) and analysed using FlowJo 9.6.2 software (Treestar). The extent of 
internalization was determined by comparing the median fluorescence intensity 
(MFI) of F-actin treated samples with F-buffer treated samples, and anti-DNGR-1 
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treated samples with isotype control treated samples. For mutant DNGR-1 proteins, 
the data were normalized to the maximal internalization induced by antibody 
treatment by using formula (MFI [F-buffer] – MFI [F-actin]) / (MFI [isotype control] – 
MFI [anti-DNGR-1]) and plotted relative to the internalization of WT. 
To confirm that 7H11 antibody binding does not interfere with 1F6 antibody binding, 
we treated cells on ice with 7H11 before fixation and analysis as described above.
  
2.6.3 B3Z-Syk reporter assay 
B3Z-Syk cells had been prepared and used in the lab previously (Ahrens et al., 
2012, Sancho et al., 2009). To compare their response to dead cells, B3Z-Syk cells 
expressing full length WT or mutant DNGR-1 proteins were plated at 1 x 105 per 
well of a flat-bottom 96-well plate in 100 µl of AIM-V medium, and previously 
UV-irradiated HeLa cells were added at indicated ratios in further 100 µl of medium. 
For plate-bound antibody stimulation, the wells were pre-coated with 100 µl of 
10 µg/ml 7H11 in PBS. As a control, medium alone was added. The cells were 
incubated for 16–18 hours at 37°C and 5% CO2, washed in PBS and lysed in 
CPRG-containing lysis buffer. LacZ activity was determined by measuring O.D. 595 
(using O.D. 655 as a reference) at multiple time points. To account for different 
levels of expression of various DNGR-1 mutants, the response to dead-cell 
stimulation was made relative to the response induced by the plate-bound antibody 
and compared to that of the WT. 
 
2.6.4 In vitro cross-presentation assay 
The assay was performed by Salvador Iborra and David Sancho (Centro Nacional 
de Investigaciones Cardiovasculares, Madrid, Spain) as described before (Iborra et 
al., 2012). RAW264.7 cells were infected with rVACV-OVA for 4 hours, 
UV-irradiated (UVC 240 mJ/cm2) or left un-irradiated, and cultured for further 
16 hours. WT or DNGR-1 KO Flt3L DCs transduced with desired constructs were 
generated as described above. On day 9 of culture, the cells were harvested, 
mixed with the rVACV-OVA infected and irradiated or non-irradiated RAW264.7 
cells for 2 hours before OVA-specific CD8+ T-cells were added. After further 
Chapter 2 Materials and Methods 
 
64 
 
6 hours of incubation, brefeldin A (Sigma-Aldrich, 5 µg/ml) being added for the last 
4 hours, the cells were fixed in 4% formaldehyde, permeabilised with 0.1% saponin, 
and stained with APC–anti–IFN-γ. Data were acquired on LSR Fortessa flow 
cytometer (BD Biosciences) and analysed using FlowJo 9.6.2 software (Treestar). 
 
2.7 Microscopy 
2.7.1 Electron cryomicroscopy 
All electron cryomicroscopy experiments were carried out by Takashi Fujii and 
Keiichi Namba (Riken Quantitative Biology Center, Osaka, Japan). Human platelet 
actin was polymerized in a 30 µl solution of 25 mM HEPES buffer (pH 7.5), 100 mM 
KCl, 1 mM MgCl2, and 1 mM ATP. F-actin and DNGR-1 were mixed in final 
concentrations of 1.8 µM and 7.6 µM, respectively. A 2.4 µl aliquot was applied 
onto a holey carbon molybdenum EM grid (R0.6/ 1.0, Quantifoil), blotted and 
plunge-frozen into liquid ethane by Vitrobot (FEI). The grid was observed at 
temperatures of ∼ 80 K using a JEOL JEM3200FSC electron cryomicroscope 
equipped with an U-type energy filter and a field emission electron gun operated at 
200 kV. Zero energy-loss images, with a slit setting to remove electrons of an 
energy-loss larger than 10 eV, were recorded on a 4k x 4k 15 µm/pixel slow-scan 
CCD camera (TemCamF415MP, TVIPS) at a magnification of 109,489 x (1.37 
Å/pixel), a defocus range of 1.0–2.0 µm and an electron dose of ∼20 electrons/Å2. 
Helical image analysis and 3D image reconstruction was carried out as previously 
described (Fujii et al.) by using the iterative helical real-space refine method 
(Egelman, 2000). The resolution of the reconstructed 3D image was determined by 
the Fourier shell correlation (FSC) method, in which the filament images were 
randomly divided into two sets, image analysis was carried out independently for 
the two sets of data to produce two 3D images, and the FSC was calculated from 
these two 3D images. 
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2.7.2 TIRF microscopy of single actin filaments 
In vitro biotinylated spectrin was allowed to adhere to a coverslip, washed, and 
G-actin mixed with F-buffer and 5 µM AF488 Phalloidin immediately beforehand 
was applied and allowed to polymerise for 5 minutes. Phalloiding-labelled short 
actin filaments were then decorated with AF-647-labelled DNGR-1 proteins and 
observed under a TIRF microscope. 
 
2.8 Statistical analysis 
For the statistical analysis of the quantification of dot blot, dead-cell staining assay 
and internalization assay, one-way ANOVA with Dunnett’s multiple comparisons 
test was performed in GraphPad Prism version 6.0 for Mac OS X (GraphPad 
Software). 
For the steady state analysis of biolayer interferometry data, non-linear regression 
(curve fit, one site – specific binding) was performed using GraphPad Prism version 
6.0 for Mac OS X (GraphPad Software). 
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Chapter 3. The neck region of DNGR-1 acts as a pH 
and ionic strength specific sensor 
3.1 Introduction 
DNGR-1 is a member of the C-type lectin superfamily and this is reflected by its 
overall domain organization (Huysamen et al., 2008, Sancho et al., 2008). The 
extracellular portion of DNGR-1 comprises a single CTLD and a neck region of 
isoform-specific length (Huysamen et al., 2008, Sancho et al., 2008). Both human 
and one of the murine isoforms have been shown to be dimeric, a property which is 
predicted to be attributable to a disulphide bond within the neck region (Huysamen 
et al., 2008, Sancho et al., 2008). 
Historically, the neck regions of both C-type lectins and other receptors used to be 
considered a mere “scaffold” on which the ligand binding domains rest and which 
connect them to the membrane and the intracellular signalling motifs. As such, the 
contribution of the neck regions to the properties and functions of receptors were 
rarely assessed and in structural studies the neck regions tended to be ignored 
altogether. This notion, however, is quickly becoming an out-dated one, as neck 
regions of multiple receptors have now been shown to regulate their various 
functional properties. Among the C-type lectins, the neck of Ly49 receptors was 
shown to regulate their binding to MHC-I molecules (Back et al., 2009) while the 
neck of DC-SIGN serves as a pH-sensor controlling oligomerization of the receptor 
(Tabarani et al., 2009).  
Consequently, when we set out to assess the properties of DNGR-1, we decided to 
use the entire extracellular domain including the neck region, rather than the 
ligand-binding domain alone. 
 
3.2 Results 
3.2.1 The cysteine in the neck region is responsible for covalent 
dimerization of both long and short mDNGR-1 
In order to assess the properties of DNGR-1, we expressed the entire extracellular 
domain (ECD) of both long and short mDNGR-1 isoforms in 293F cells as 
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described previously (Ahrens et al., 2012). Consistently with previous reports 
(Ahrens et al., 2012, Sancho et al., 2009, Sancho et al., 2008), long mDNGR-1 
ECD expressed as a disulphide-bonded homodimer, which could under normal 
conditions be reduced to its constitutive monomers using reducing agents such as 
dithiothreitol (DTT) or β-mercaptoethanol (β-ME) (Fig 3.1A). Contrary to a previous 
report describing expression of the short isoform as a monomer (Huysamen et al., 
2008), we observed the ECD protein as a disulphide-bonded dimer (Fig 3.1A), 
consistent with the presence of the putative dimerization cysteine at position 94 in 
both isoforms. Supporting the idea that the cysteine in the neck region is 
responsible for covalent dimerization of DNGR-1, mutating it to serine (C94S) 
resulted in a mutant protein with electrophoretic mobility corresponding to that of a 
monomer under both reducing and non-reducing conditions (Fig 3.1B). The 
mutation, however, had a strong adverse effect on the expression efficiency (data 
not shown).  
All mouse DNGR-1 isoforms contain two putative N-glycosylation sites (Gavel and 
von Heijne, 1990) – one in the neck region and one in the CTLD itself (Fig 3.1C). 
While the long DNGR-1 isoform has been shown to be glycosylated (Sancho et al., 
2008), the short isoform has been reported to be non-glycosylated (Huysamen et 
al., 2008). In an attempt to reconcile these contradictory observations, we 
subjected both long and short DNGR-1 ECD isoforms expressed in 293F cells to 
deglycosylation treatment using PNGase F, followed by analysis by SDS-PAGE 
and Western blot (Fig 3.1D). Interestingly, we observed a clear shift in the 
electrophoretic mobility of both proteins after the deglycosylation treatment, 
suggesting that both are decorated with N-linked glycans (Fig 3.1D), consistent 
with the conservation of the glycosylation sites.  
Chapter 3 Results 
 
68 
 
 
Figure 3.1 Long and short mouse DNGR-1 isoforms are expressed as 
glycosylated, disulphide-bonded dimers 
A, Supernatants after protein production of long and short DNGR-1 ECD were 
prepared for SDS-PAGE and Western Blot analysis under reducing (100 mM DTT 
or 250 mM β-mercaptoethanol) or non-reducing conditions. B, Supernatant after 
protein production of C94S mutant was 200x concentrated and analysed by SDS-
PAGE and Western blot under reducing and non-reducing conditions alongside 
control WT supernatant. C, Alignment of the regions of long and short DNGR-1 
isoforms containing the putative N-glycosylation sites (highlighted by the red 
rectangle). D, Supernatants after protein production of long and short DNGR-1 
ECD were denatured by treatment with DTT at 100°C and treated with PNGase-F 
overnight, or mock-treated without the addition of the enzyme. After the treatment 
all samples were analysed by SDS-PAGE and Western Blot. HRP-conjugated anti-
FLAG antibody was used for detection of all proteins. Numbers on the side of blots 
indicate positions of MW markers. 
 
3.2.2 DNGR-1 can form reduction insensitive dimers 
Surprisingly, we noticed that under certain conditions, the dimers of DNGR-1 ECD 
could become resistant to DTT-mediated reduction and maintained their dimeric 
status even in the presence of the reducing agent.  
We speculated that ligand binding might cause the reduction insensitivity of DNGR-
1 dimers. To test this hypothesis, we mixed a constant amount of purified DNGR-1 
ECD with increasing amounts of in vitro polymerised F-actin, or F-actin buffer only 
as a control. Presence of F-actin, however, had no effect on the sensitivity of 
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DNGR-1 ECD to reducing agents (Fig 3.2A). Diluting DNGR-1 ECD into buffers of 
lower pH and ionic strength proved to be effective in inducing the reduction 
insensitive state though (Fig 3.2B). We tested buffers of different ionic strengths 
and pH (the range of pH 6.5 – 8.0 and ionic strength 15 – 250 mM), while keeping 
the buffering capacity of all buffers constant. After analysis by SDS-PAGE with 
100 mM DTT, we observed a clear trend towards higher abundance of reduction 
insensitive dimers as the pH and ionic strength decreased (Fig 3.2C). Interestingly, 
the conditions under which the reduction insensitive dimers were abundant 
correspond to the conditions found in the endocytic pathway, while the conditions 
where no reduction insensitive dimers were observed correlate with those in the 
extracellular milieu (Scott and Gruenberg, 2011). 
 
 
Figure 3.2 Reduction insensitive dimers of DNGR-1 ECD can be induced by low 
pH and ionic strength 
A, 0.25 µg of DNGR-1 ECD was mixed with increasing amount of in vitro 
polymerised F-actin (0.15 – 10 µM), and reduction sensitivity of DNGR-1 was 
assessed by reducing SDS-PAGE and Western blot. Numbers on the side of blots 
indicate positions of MW markers. B, 0.25 µg of DNGR-1 ECD was diluted into 
10 mM Tris buffer of indicated pH (left panel) or into 10 mM Tris pH 7.4 buffer 
supplemented with increasing amounts of NaCl (1 – 250 mM), and reduction 
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sensitivity of DNGR-1 was assessed by reducing SDS-PAGE and Western blot. 
Numbers on the side of blots indicate positions of MW markers. Reduction-resistant 
dimers are indicated with an * and reduction-sensitive protein with a +. C, 0.25 µg 
of DNGR-1 was diluted into thirty-six different buffers of different pH and ionic 
strength, and its reduction sensitivity was assessed by reducing SDS-PAGE and 
Western blot. The strength of bands corresponding to dimer and monomer was 
determined densitometrically, and their ratio was plotted as function of ionic 
strength and pH. HRP-conjugated anti-FLAG antibody was used for detection of all 
proteins. 
 
3.2.3 Conformational change in the neck region is responsible for the 
formation of reduction insensitive dimers 
Since the neck region is responsible for dimerization of DNGR-1, we hypothesized 
that a conformational change in this portion of the protein could be responsible for 
the buffer-dependent reduction insensitivity of DNGR-1 ECD. Conceivably, the 
effect could be mediated either by means of sterical protection of the disulphide 
bond from the reducing agents, or by conformational rearrangement that makes the 
disulphide bond dispensable for maintaining the dimeric status of the protein. In 
either case, a change in the structural elements of the protein would need to be 
involved. To test this hypothesis, we subjected the reduction insensitive form of 
DNGR-1 ECD to mildly denaturing (Leammli buffer) or strongly denaturing 
(8 M urea) conditions before applying DTT. As predicted, strongly denaturing 
conditions abolished the ability of DNGR-1 ECD to resist reduction, while under 
weakly denaturing conditions reduction insensitive dimers could be observed. As 
expected, in the absence of reduction agents, the protein maintained its dimeric 
status regardless of the denaturing conditions (Fig 3.3A). To the same end, we 
gradually increased the stringency of the heat denaturation step by increasing the 
time of boiling in Laemmli buffer. When analysed by Western blot, DNGR-1 ECD 
appeared exclusively as a monomer after 5 minutes of boiling under neutral 
conditions, while the protein kept under mildly acidic conditions (MES pH 6.1) was 
not completely reduced by 15 minutes of treatment (Fig 3.3B).  
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Figure 3.3 Conformational change in DNGR-1 is responsible for the formation of 
reduction-resistant dimers 
A, 0.25 µg of DNGR-1 ECD was diluted into PBS or 10 mM MES pH 6.1 buffer, and 
its reduction sensitivity was tested under mildly (Laemmli buffer) or strongly 
denaturing (8 M urea) conditions by reducing SDS-PAGE and Western blot. B, 
0.25 µg of DNGR-1 ECD was diluted into PBS or 10 mM MES pH 6.1 buffer, and its 
reduction sensitivity after different length of heat-denaturation in Laemmli buffer 
was tested by reducing SDS-PAGE and Western blot. HRP-conjugated anti-FLAG 
antibody was used for detection of all proteins. Numbers on the side of blots 
indicate positions of MW markers. Reduction-resistant dimers are indicated with an 
* and reduction-sensitive protein with a +. 
 
3.2.4 The conformational change of DNGR-1 is reversible 
To evaluate reversibility of the conformational change, we subjected DNGR-1 ECD 
to mildly acidic treatment (MES pH 6.1) to induce the reduction insensitivity, or kept 
it in PBS as a control. Half of the MES-treated sample and the PBS sample were 
then dialyzed against PBS and together with the un-dialyzed MES sample analysed 
using reducing SDS-PAGE and Western blot. As expected, we observed increase 
in reduction insensitivity in the protein kept under mildly acidic condition. However, 
the protein that had been MES-treated and dialysed back into PBS afterwards 
showed no increase in reduction insensitivity (Fig 3.4). This suggests that the 
conformational change is not just non-specific aggregation of the protein but rather 
a controlled, reversible process. 
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Figure 3.4 The conformational change in DNGR-1 is reversible 
1 µg of DNGR-1 ECD was transferred into MES pH 6.1 and 0.5 µg into PBS. Half 
of the MES sample and the whole PBS sample were dialyzed against 2 l of PBS 
overnight at 4°C. After dialysis, all the samples were prepared for SDS-PAGE and 
Western blot. HRP-conjugated anti-FLAG antibody was used for detection of all 
proteins. Numbers on the side of the blot indicate positions of MW markers. 
Reduction-resistant dimers are indicated with an * and reduction-sensitive protein 
with a +. 
 
3.2.5 The neck region is sufficient for the conformational change 
To test whether the neck region is involved in and sufficient for the formation of 
reduction insensitive dimers, we generated a chimeric ECD where the neck region 
of DNGR-1 was fused to the CTLD of another C-type lectin, Dectin-1 (C9C7 
chimera; Fig 3.5A). As expected, unlike the Dectin-1 ECD control, the chimeric 
ECD expressed as a disulphide-bonded homodimer (Fig 3.5B), consistent with our 
data showing that the neck region mediates dimerization of DNGR-1. Notably, 
under conditions, which induced reduction insensitive state in DNGR-1 ECD, the 
C9C7 chimera was also refractory to DTT-mediated reduction (Fig 3.5C). We 
conclude that the neck region of DNGR-1 can serve as a sensor of pH and ionic 
strength responding to some conditions by undergoing a reversible conformational 
switch.  
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Figure 3.5 DNGR-1 neck region is sufficient and necessary for the formation of 
reduction-resistant ECD dimers 
A, Schematic depiction of DNGR-1, Dectin-1 and the C9C7 chimeric receptor B, 
protein production supernatants containing ECD of DNGR-1, Dectin-1 and C9C7 
chimera were prepared for SDS-PAGE and Western blot under non-reducing 
conditions. C, Supernatants after protein production of indicated proteins were 
diluted into PBS or pH 6.1 MES buffer and analysed using SDS-PAGE and 
Western blot under reducing conditions. HRP-conjugated anti-FLAG antibody was 
used for detection of all proteins. Numbers on the side of blots indicate positions of 
MW markers. Reduction-resistant dimers are indicated with an * and 
reduction sensitive protein with a +. 
 
 
3.2.6 Ability to undergo pH and ionic strength-induced conformational 
change is conserved between mouse and human DNGR-1 isoforms 
To confirm that the ability to undergo conformational change is not an 
isoform-specific property, we made recombinant proteins corresponding to the ECD 
of human and both long and short mouse DNGR-1 isoforms, and tested their 
reduction sensitivity in different buffers. All of the proteins were expressed as 
disulphide-bonded homodimers, and when subjected to weakly acidic conditions 
(pH 6.1) showed increased resistance to DTT-mediated reduction (Fig 3.6). This 
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suggests that the ability to undergo the conformational change is an evolutionarily 
conserved property of DNGR-1. 
 
Figure 3.6 Formation of reduction-resistant dimers is conserved between various 
DNGR-1 isoforms 
Supernatants after protein production in 293F cells were harvested and diluted into 
indicated buffers at a 2:3 ratio and analysed using reducing SDS-PAGE and 
Western blot. HRP-conjugated anti-FLAG antibody was used for detection of all 
proteins. Numbers on the side of blots indicate positions of MW markers. 
Reduction-resistant dimers are indicated with a * and reduction-sensitive protein 
with a +. 
 
3.2.7 Membrane-bound DNGR-1 can undergo the conformational change 
DNGR-1 proteins in which we observed the conformational change were all 
expressed as soluble ECDs, lacking the transmembrane and intracellular domains. 
To assess whether the phenomenon could be observed in the context of the 
full-length protein, we lysed DNGR-1-expressing transfected cells under neutral or 
mildly acidic conditions and tested the reduction sensitivity of DNGR-1 contained in 
the lysates. While SDS-lysis under neutral conditions resulted in complete 
reducibility of DNGR-1 dimers, SDS-lysis under mildly acidic conditions induced 
reduction insensitive state in the full-length receptor (Fig 3.7, left panel). Similar 
results were also obtained using MuTu DC1940 CD8α+-like DC line (Fuertes 
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Marraco et al., 2012) that expresses DNGR-1 from its endogenous locus (Fig 3.7, 
right panel). 
 
 
Figure 3.7 Membrane-bound DNGR-1 can undergo the conformational change 
Cells retrovirally transduced to overexpress mouse DNGR-1 (long isoform; left 
panel) or cells endogenously expressing DNGR-1 (right panel) were lysed in 1% 
SDS in PBS or 10 mM BisTris pH 5.5 buffer and prepared for reducing SDS-PAGE 
and Western blot. Monoclonal anti-DNGR-1 antibody (397) in combination with 
HRP-coupled anti-rat monoclonal antibody was used for detection. Numbers on the 
side of blots indicate positions of MW markers. Reduction-resistant dimers are 
indicated with a * and reduction-sensitive protein with a +. 
 
3.2.8 The conformational change happens at the level of tertiary structure 
In order to characterize the conformational change further, we made use of circular 
dichroism (CD). Far-UV CD spectra of proteins are representative of their 
secondary structure content, and such analysis can reveal the relative contribution 
of elements of secondary structure to the overall structural composition of the 
protein. In contrast, near-UV CD spectra are specific for particular residues (Phe, 
Tyr, Trp) and disulphide bonds, and are reflective of the residues’ environment and 
dipole orientation, and the torsion angle of the disulphide bonds (Martin and 
Schilstra, 2008). First, we utilized far-UV CD to determine if the conformational 
Chapter 3 Results 
 
76 
 
change we observed happens at the level of secondary structure. We acquired 
spectra of both long mouse and human DNGR-1 ECDs under neutral (PBS) and 
mildly acidic (MES pH 6.1) conditions, and we observed almost perfect overlap 
between the two conditions (Fig 3.8A). Detailed analysis revealed for both mouse 
and human ECDs only a very minor increase in the content of alpha helical 
structure, corresponding to approximately four residues (Table 4).  
 
  alpha helix beta sheet beta turn random 
mDNGR-1 
ECD 
PBS 16.1 % 22.5 % 17.1 % 44.3% 
MES 17.8 % 21.8 % 17.0 % 43.5% 
hDNGR-1 
ECD 
PBS 22.3 % 21.3% 19.5 % 37.2% 
MES 24.2 % 20.7 % 20.8 % 34.2 % 
Table 4 Relative contributions of the elements of secondary structure to mouse 
and human DNGR-1 ECD under different conditions 
 
Interestingly, the different amount of disordered structure observed in mouse and 
human isoform (44% vs. 37% in PBS; Table 4) corresponds to approximately 
twenty six residues. The human and mouse isoforms differ by the presence of an 
extra exon coding for a stretch of twenty-six residues in the neck region of mouse 
DNGR-1. Thus, our data suggest that the amino acids in the extra exon of mouse 
long DNGR-1 isoform form an unstructured loop, and that the conformational 
change we observed does not happen at the level of secondary structure. 
With no large change in the ECD secondary structure, we speculated that mutual 
repositioning of the two neck regions within the dimer might be at the root of the 
observed reduction resistance. To test this hypothesis, we acquired near-UV CD 
spectra of long mouse DNGR-1 ECD under neutral (PBS) and mildly acidic (MES 
pH 6.1) conditions (Fig 3.8B). The spectra showed clear differences, with a broad 
band between 270 nm and 350 nm indicating a change in the torsion angle of a 
disulphide bond, and narrow bands in the area around 280 nm and 290 nm 
indicating a change in the environment of at least one tryptophan residue. Taken 
together, near-UV and far-UV CD thus suggest that a change in the tertiary 
structure, but not secondary structure happens when DNGR-1 undergoes transition 
to the reduction insensitive form. These data are consistent with a model where 
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repositioning of the neck regions within the dimer results in protection of the 
disulphide bond, explaining the phenomenon of reduction resistance of DNGR-1 
under certain conditions. To make a clear distinction of the two conformational 
states, we propose to call the reduction sensitive form “Type-1 dimer” and the 
reduction insensitive form “Type-2 dimer” (Fig 3.8C). 
 
 
Figure 3.8 A change in the tertiary structure is responsible for the formation of 
reduction-resistant dimers 
A, Mouse and human DNGR-1 ECD were diluted to the final concentration of 
150 µg/ml in PBS or 10 mM MES pH6.1 buffer and 20 far-UV spectra were 
acquired for each condition (red and black lines depict the composite curve for 
each condition) B, Mouse DNGR-1 ECD was diluted to the final concentration of 
500 µg/ml in PBS or 10 mM MES pH 6.1 buffer and 20 near-UV spectra were 
acquired for each condition (red and black lines depict the composite curve for 
each condition and the blue line shows the difference between the two). C, 
Schematic representation of the suggested conformational states of DNGR-1. 
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3.2.9 Mutations in the neck region affect Type-2 dimer formation and 
dimerization of DNGR-1 
We observed Type-2 dimer formation in both mouse and human DNGR-1, 
suggesting that the part of the neck region involved in the process is conserved 
between the two proteins. Hence, in order to assess which parts of the neck play a 
role in Type-2 dimer formation, we genetically removed overlapping blocks of ten or 
eleven amino acids from the conserved part of the neck (K57 – L66 (Δ1), L64 – I73 
(Δ2), L72 – L82 (Δ3), N81 – T90 (Δ4), R87 – A96 (Δ5) and Q95 – S104 (Δ6) (Fig 
3.9A)), expressed the resulting constructs as ECDs, and tested their ability to form 
Type-2 dimers (Fig 3.9B). The mutants devoid of the first two blocks (Δ1 and Δ2) 
expressed to a comparable extent to the WT and showed no phenotype with 
respect to Type-1 or Type-2 dimers formation. The expression of Δ3 mutant was 
significantly reduced in comparison to the WT, even though it also exhibited no 
obvious phenotype. Δ6 mutant failed to express completely (Fig 3.9B). On the other 
hand, Δ4 mutant expressed as efficiently as the WT, but showed enhanced Type-2 
dimer formation even under neutral conditions (Fig 3.9B). Δ5 mutant lacks the 
dimerization cysteine (C94), and consequently behaves as a monomer when 
analysed in both reducing and non-reducing conditions using SDS-PAGE (Fig 
3.9B). Unlike the C94S mutant, however, the Δ5 mutant expressed as efficiently as 
the WT (Fig 3.9B). Reintroduction of a cysteine residue alone into Δ5 mutant 
(Δ5+C) resulted in a drastic decrease of expression (Fig 3.9C), which could be 
rescued by mutating all the residues in block 5 except for the cysteine to alanines 
(Δ5A+C). Furthermore, Δ5A+C protein was dimeric with an increased propensity 
for Type-2 dimer formation (Fig 3.9C), presumably due to partial overlap of blocks 4 
and 5 (Fig 3.9A).  
To confirm that the effects we saw with the “block mutants” were a specific result of 
the loss of the different regions and not just a non-specific consequence of parts of 
the neck region getting “out of sync” due to part of the helices missing, we 
substituted all the residues within blocks 3, 4 and 6 with strings of alanines of 
appropriate lengths and expressed the proteins as soluble ECDs. Importantly, 
replacing all the residues in block 4 (Δ4A) resulted in a protein mimicking the 
behaviour of the Δ4 mutant (Fig 3.9D), suggesting a specific involvement of some 
of the residues present in this region. Interestingly, and unlike the Δ3 and Δ6 
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mutants, the mutants with residues in blocks 3 and 6 replaced with alanines (Δ3A 
and Δ6A) got expressed, even though in the case of Δ6A to lower extent than the 
WT. Notably, while Δ3A mutant showed no phenotype, Δ6A mutant failed to form 
Type-2 dimers under conditions which were effective in inducing their formation in 
the WT protein (Fig 3.9D).  
We noticed a putative N-glycosylation site (NxT sequence) (Gavel and von Heijne, 
1990) at the boundary of blocks 3 and 4, which is disrupted in both Δ3 and Δ4 
mutants (Fig 3.9A). Consistent with this site being glycosylated in mouse DNGR-1, 
both Δ3A and Δ4A mutants showed higher electrophoretic mobility than WT or Δ6A 
mutant (Fig 3.9D). As Δ3A and Δ4A mutants do not exhibit the same phenotype, 
however, the glycosylation appears not to be involved in Type-2 dimer formation.  
Taken together, our data are consistent with a model where residues in the block 4 
serve as spring “pushing” the neck regions apart, preventing Type-2 dimer 
formation under normal conditions, while residues in the block 6 appear to be 
directly responsible for Type-2 dimer formation. Residues in the block 5 appear to 
serve as mere “filling,” allowing for covalent dimerization through the disulphide 
bond, and their exact identity seems largely irrelevant, consistent with their limited 
conservation between mouse and human DNGR-1 (Fig 3.9A). 
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Figure 3.9 Distinct parts of the neck region contribute to regulation of Type-2 
dimer formation 
A, Sequences of the neck region of human and long and short isoform of mouse 
DNGR-1 aligned in Clustal X software. Parts of the neck corresponding to the block 
deletions are depicted as green bars. B,C and D, Supernatants after production of 
indicated ECD proteins (mouse, long isoform) were diluted into indicated buffers in 
1:2 ratio and analysed by SDS-PAGE and Western blot under reducing or 
non-reducing conditions. HRP-conjugated anti-FLAG antibody was used for 
detection of all proteins. Numbers on the side of blots indicate positions of MW 
markers. Reduction-resistant dimers are indicated with an * and reduction-sensitive 
protein with a +. 
 
3.2.10 The conformational change does not grossly affect oligomerization 
status of DNGR-1 
The neck region of another C-type lectin, DC-SIGN has previously been reported to 
serve as a pH-sensor regulating oligomerization of the receptor (Tabarani et al., 
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2009). To test whether the neck region of DNGR-1 could serve a similar purpose, 
we tested the oligomerization status of DNGR-1 ECD under different conditions 
using multi-angle light scattering (MALS). While we observed no gross changes in 
the oligomerization status, we saw subtle changes in the apparent molecular 
weight ranging between 60 – 90kDa in different buffers (data not shown). The 
reasons for this heterogeneity are currently unclear and focus of an on-going 
investigation, however, our data suggest that the oligomerization status of DNGR-1 
is not grossly affected by the formation of Type-2 dimers. 
 
3.2.11 Type-2 dimer formation does not affect the ability of DNGR-1 to bind 
F-actin 
A pH-induced conformational change in another C-type lectin, DEC205, has 
recently been shown to allow the protein to recognise a ligand in apoptotic and 
necrotic cells (Cao et al., 2015). Consequently, we set out to determine if the 
conformational change in DNGR-1 affects its ability to bind F-actin. To this end we 
utilised the dot blot assay (Ahrens et al., 2012) (Fig 3.10) where decreasing 
amounts of in vitro polymerised actin were spotted onto a membrane, and the 
membrane was blocked and incubated with DNGR-1 WT, Δ4 or Δ6A mutant ECDs 
in PBS or MES pH 6.1 buffers. Binding of ECD was then revealed using anti-FLAG 
antibody. To account for possible artefacts caused by different ability of the anti-
FLAG antibody to bind under different conditions, two pieces of membrane were 
incubated with each DNGR-1 protein under each condition, and one of them was 
then switched to the second buffer condition for antibody detection step, while the 
other was kept in the same buffer. Using this setup, we could not observe any 
differences in the binding ability of WT, Δ4 or Δ6A DNGR-1 ECDs in any of the 
buffers (Fig 3.11), suggesting that the conformational change is not involved in the 
regulation of DNGR-1 ligand-binding. 
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Figure 3.10 The conformational change does not affect binding of DNGR-1 to 
F-actin 
Decreasing amounts of F-actin were spotted onto a nitrocellulose membrane and 
binding of indicated DNGR-1 ECD proteins (mouse, long isoform) was tested under 
conditions shown in the lower right corner, first column. HRP-conjugated anti-FLAG 
antibody was used for detection in conditions shown in the lower right corner, 
second column. 
 
3.2.12 The phenotypes observed in “block mutant” ECDs are maintained 
when expressed as transmembrane proteins. 
To test the functional capability of the Δ4 and Δ6A DNGR-1 mutants in cells, we 
re-made them as transmembrane proteins and retrovirally introduced them into 
Phoenix cells. First, to confirm that the phenotypes we observed for the soluble 
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ECD “block mutant” proteins are also valid for transmembrane proteins, we lysed 
the Phoenix cells in 1% SDS in either 10 mM MES pH 6.1 or PBS buffers and 
prepared the samples for reducing SDS-PAGE and Western blot analysis. As 
expected, WT protein appeared exclusively as Type-1 dimer in the PBS sample, 
while lysis in the MES buffer induced Type-2 dimer formation (Fig 3.11). On the 
other hand, the Δ4 mutant appeared in the form of Type-2 dimers in both buffers, 
while the Δ6A mutant exhibited no Type-2 dimer formation in either (Fig 3.11). In 
the case of the Type-2 dimer samples, (WT in MES buffer and Δ4 mutant in both 
conditions), we observed multiple bands, seemingly corresponding to 
reduction-insensitive higher oligomers (Fig 3.11). We never observed similar 
phenomenon for the soluble protein, and given that under normal conditions 
DNGR-1 dimerization is mediated by the single cysteine residue in the neck region, 
it is unclear how the higher oligomers arise. 
 
 
Figure 3.11 Type-2 dimer formation in transmembrane "block" mutants 
Cells expressing indicated proteins (mouse, long isoform) were lysed in 1% SDS in 
PBS or 10 mM MES pH 6.1 buffer and the lysates were analysed by reducing 
SDS-PAGE and Western blot. Signal was revealed using anti-DNGR-1 (397) 
followed by HRP-conjugated anti-rat antibodies. Numbers on the side of the blot 
indicate positions of MW markers. Reduction-resistant dimers are indicated with a * 
and reduction-sensitive protein with a +. 
 
3.2.13 DNGR-1 internalization in response to stimuli 
When cross-linked by antibody or F-actin, DNGR-1 expressed both endogenously 
in dendritic cells and heterologously in unrelated cells gets internalized (Huysamen 
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et al., 2008, Sancho et al., 2008), which can be read out by flow cytometry as a 
decrease in surface staining (Fig 3.12). This effect is not caused by blocking of the 
epitope recognised by the detection antibody, as treatment on ice results in only 
minimal decrease in signal (Fig 3.13).  
 
 
Figure 3.12 Crosslinking of DNGR-1 induces its internalization 
A, Dendritic cells generated by culture of mouse bone marrow in the presence of 
Flt3 ligand were treated for 45 minutes as shown, fixed in formaldehyde, stained for 
DNGR-1, CD172a (SIRPα) and B220, and analysed by flow cytometry. The 
CD8α+-like dendritic cells were identified as CD172a-, B220- and their surface 
staining of DNGR-1 was assessed. One representative of three biological 
replicates (lower panel) and quantitation of the three (upper panel) are shown. The 
bars represent mean ± s.d., *P < 0.05, **P < 0.01, ***P < 0.001; One-way ANOVA 
with Tukey’s multiple comparison test. B, Full-length DNGR-1 was retrovirally 
introduced into Phoenix cells. The cells were treated for 45 minutes as shown, fixed 
in formaldehyde, and stained for DNGR-1. The intensity of DNGR-1 staining was 
assessed by flow cytometry. One representative of three experimental replicates 
(lower panel) and quantitation of the three (upper panel) are shown. The bars 
represent mean ± s.d., *P < 0.05, **P < 0.01, ***P < 0.001; One-way ANOVA with 
Tukey’s multiple comparison test. 
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Figure 3.13 DNGR-1 cross-linking on ice does not result in decreased staining 
Phoenix cells stably expressing DNGR-1 were treated with anti-DNGR-1 antibody 
(clone 7H11) and incubated at 37°C or on ice for 30 minutes, fixed in 
formaldehyde, surface-stained for DNGR-1 (clone 1F6) and analysed by flow 
cytometry. 
 
3.2.14 The ability of Δ4 and Δ6A DNGR-1 mutants to undergo 
ligand-dependent endocytosis is unaffected 
To assess the ability of Δ4 and Δ6A mutants to be internalised upon stimulation, we 
treated Phoenix cells expressing transmembrane WT, Δ4 or Δ6A DNGR-1 with 
F-actin, anti-DNGR-1 antibody (7H11), F-buffer or isotype-matched control 
antibody for 1 hour at 37°C. Following the incubation, the cells were fixed and 
stained for surface DNGR-1 with anti-DNGR-1 antibody (1F6). As expected, WT 
protein got internalised upon both F-actin and antibody treatment, while control 
treatments induced no detectable receptor internalization. Both mutants mimicked 
the behaviour of the WT and internalised to comparable extent (Fig 3.14), 
suggesting that the neck region is not involved in the regulation of the 
internalization process. 
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Figure 3.14 Type-2 dimer formation does not affect the ability of DNGR-1 to 
internalize 
Phoenix cells expressing indicated mutant or WT DNGR-1 proteins were treated 
with F-actin, F-buffer, anti-DNGR-1 antibody or isotype-matched antibody of 
irrelevant specificity for 60 minutes, fixed in formaldehyde, surface-stained for 
DNGR-1 and analysed by flow cytometry. One representative of two experiments is 
shown. 
 
3.3 Discussion 
Multiple isoforms of mouse DNGR-1 have been described previously. Surprisingly, 
disparate results regarding glycosylation and dimerization of the proteins have 
been reported. While human and one of the mouse isoforms were shown to be 
dimeric and glycosylated (Huysamen et al., 2008, Sancho et al., 2008), another 
mouse isoform was reported to be monomeric and non-glycosylated (Huysamen et 
al., 2008). In contrast, our data show that proteins corresponding to the ECD of 
both of the mouse isoforms both behave as disulphide-bonded, glycosylated 
dimers. This observation is in line with the fact that both the dimerization cysteine 
and the glycosylation sites are conserved between the two isoforms. It is possible 
that proper glycosylation of certain DNGR-1 isoforms may be required for their 
dimerization and that DNGR-1 expressed in NIH3T3 cells (Huysamen et al., 2008) 
is not glycosylated, in the same manner as DNGR-1 expressed in 293F cells (this 
study). 
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Interestingly, we show that DNGR-1 can undergo a conformational change in a 
manner independent of ligand binding, but induced by changes in pH and ionic 
strength. The conformational change affects the neck region, and appears to 
happen predominantly at the level of tertiary structure, suggesting a rearrangement 
of the α-helices that likely form the majority of the neck. pH-induced conformational 
changes have been described for multiple proteins, and mechanistically, they often 
are mediated by protonation of one or more histidine residues (Dai et al., 2014, 
Kalani et al., 2013, Krukenberg et al., 2009, Cao et al., 2015). This is due to the 
pKa of the His side chain, which falls in physiologically relevant pH-range, allowing 
formation of a His+ cation, and consequently repulsion between His+ and other 
positively charged residues (Harrison et al., 2013). The neck region of DNGR-1, 
however, does not contain any conserved histidine residues (Fig 3.9A), suggesting 
that a different mechanism needs to be at play. Notably, in addition to histidine, 
negatively charged residues have also been implicated in pH-induced 
conformational changes (Yeo et al., 2014). Depending on their environment, these 
residues can have heightened pKa, also allowing protonation in a physiologically 
relevant pH-range. Contrary to the protonation of histidine residues, protonation of 
glutamic or aspartic acid does not result in the introduction of a repulsive force but 
rather in its relief due to the Glu- or Asp- switching to their uncharged states 
(Harrison et al., 2013). The regions of the DNGR-1 neck which appear to be 
involved in the conformational change based on our experiments with “block 
mutants,” however, do not contain any conserved negatively charged residues 
either (Fig 3.9A). On the other hand, the regions we putatively identified contain 
multiple hydrophobic residues and residues potentially capable of forming 
hydrogen bonds and salt bridges. While neither of these interactions can provide 
destabilizing forces quite like repulsion, in sufficient quantity these forces can 
contribute to and perhaps even be sufficient for pH-sensitive conformational 
rearrangements (Harrison et al., 2013). Importantly, involvement of salt bridges 
could help explain the effects of ionic strength (Hendsch and Tidor, 1994) that we 
observed, while involvement of hydrogen bonds could explain the effects of pH 
(Wood, 1974). Finally, both pH and ionic strength can affect hydrophobicity of 
amino acids and by extension the strength of hydrophobic interactions (Gulyaeva et 
al., 2003). If the model outlined above is correct and multiple amino acids 
contribute to the overall effect while no one single one is essential, then singly 
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mutating any residue within the neck region should result in no observable 
phenotype. Arguing in favour of such model, despite an extensive mutagenesis 
effort (data not shown), we have so far been unable to identify a single residue 
within the neck, mutation of which would significantly affect Type-2 dimer formation. 
pH-induced conformational changes have been shown to regulate function of other 
C-type lectin receptors. Namely, the neck region of DC-SIGN has been shown to 
serve as a pH and ionic strength-specific sensor regulating oligomerization status 
of the receptor, allowing release of bound ligands into endosomes (Tabarani et al., 
2009). Similarly, pH-induced conformational change in DEC205 has been shown to 
correlate with the receptor binding to as-of-yet unidentified ligand in apoptotic and 
necrotic cells (Cao et al., 2015). The conformational change in DNGR-1, however, 
does not markedly affect either of these properties. Notably, the conformational 
change happens between the conditions that DNGR-1 would encounter on cell 
surface and within the endosomal pathway (Scott and Gruenberg, 2011), 
suggesting that it might allow DNGR-1 to regulate its function based on its 
subcellular localization.  
It has been previously suggested that the hemITAM motifs of dimeric C-type lectin 
receptors could function as a single ITAM motif, allowing recruitment of the two 
SH2 domains of the Syk kinase (Sancho and Reis e Sousa, 2012, Hughes et al., 
2010). Reported flexibility between the two SH2 domains as well as the ability of 
Syk to bind to ITAM motifs with linkers between the two phosphorylated tyrosines 
differing in length by as much as 50% (Kumaran et al., 2003) argues in favour of 
such model. It is still easily conceivable though that certain positioning of the two 
hemITAMs might not be permissive for Syk binding, while others could be more 
favourable. Changes in the secondary structure of the extracellular portion of 
single-pass transmembrane proteins are generally unable to transmit across 
plasma membrane to the intracellular portions involved in signalling. This, however, 
does not apply to dimeric receptors, where changes in the tertiary structure and/or 
relative positioning of the monomers within the dimer have the potential to translate 
into repositioning of the intracellular domains, and vice versa, as extensively 
described for example for integrins (Shimaoka et al., 2002). Furthermore, at least 
for some receptors, there appear to be not only “on” and “off” positions, but the 
relative positioning of the extracellular domains can result in different modalities of 
signalling (Moraga et al., 2015, Rowlinson et al., 2008). This is similar to the 
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concept of “biased signalling” where one G-protein coupled receptor (GPCR) can 
activate different pathways depending on the bound ligand (Drake et al., 2008). It is 
thus tempting to speculate that the conformational change in the neck of DNGR-1 
could transmit to the intracellular portion, and affect positioning of the two 
hemITAM signalling motifs, in turn controlling the ability of DNGR-1 to signal based 
on its cellular localization. Of course other possibilities unrelated to signalling, 
including for example unmasking of a protease cleavage site or docking site for 
another protein cannot be ruled out at present. Obviously, the first experiment to do 
in order to assess the relevance of the conformational change for biology of 
DNGR-1 is the cross-presentation assay with DNGR-1 KO DCs transduced with Δ4 
and Δ6A mutant proteins. Unfortunately, due to technical reasons we have so far 
been unable to conduct such experiment, but the work is on-going. 
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Chapter 4. Biophysical and Structural 
Characterization of DNGR-1 : F-actin interaction 
4.1 Introduction 
DNGR-1 has recently been reported to specifically recognize F-actin (Ahrens et al., 
2012, Zhang et al., 2012). While other members of the C-type lectin family have 
also been shown to bind protein ligands (Sancho and Reis e Sousa, 2012), the 
specificity for F-actin appears to be unique to DNGR-1. This suggests that the only 
way to gain insight into the interaction is by directly determining its biophysical 
characteristics, and solving the three-dimensional (3D) structure of DNGR-1 in 
complex with F-actin. 
X-ray crystallography has been an extremely successful method for determining 3D 
structure of proteins ranging in size from several amino acids to complexes as 
large as ribosome. In fact, the large majority of the approximately 100 000 protein 
structures currently deposited in the Protein Data Bank have been determined 
using this powerful technique (Wlodawer et al., 2013). The critical condition for 
using X-ray crystallography, however, is very high degree of purity and 
homogeneity of the analysed sample. Given the inherent heterogeneity of F-actin, 
any attempt at using this technique to determine the structure of F-actin in complex 
with DNGR-1 would consequently be bound to fail. 
Hence, the technique of choice to accomplish such a goal is electron microscopy. 
Electron microscopy has been successfully used for imaging actin filaments, and 
with the advent of electron cryomicroscopy with helical image analysis, the 
resolution of F-actin structures has been increased to 6.6 Å, allowing resolution of 
all the elements of secondary structure, in turn making modelling of the structure at 
atomic resolution possible (Fujii et al., 2010). 
Consequently, in order to obtain structure of DNGR-1 in complex with F-actin we 
established collaboration with Takashi Fujii and Keichii Namba (Riken Quantitative 
Biology Center, Osaka, Japan). They used DNGR-1 ECD prepared in our 
laboratory to make preparations of DNGR-1:F-actin complexes that were then 
subjected to electron cryomicroscopy and helical image analysis to derive the 
structure of F-actin decorated with DNGR-1. As these results form the foundation of 
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my ensuing work, they have been included here in the first few figures and 
acknowledged in figure legends. The validation of the structure was subsequently 
carried out by me and constitutes the remainder of the chapter.  
 
4.2 Results 
4.2.1 Electron cryomicroscopy reveals uncommon mode of binding of 
DNGR-1 to F-actin 
In order to obtain the structure of DNGR-1 in complex with F-actin, we expressed 
and purified the extracellular domain (ECD) of mDNGR-1 as described previously 
(Ahrens et al., 2012). The protein was used to decorate in vitro polymerised human 
platelet actin filaments and the complexes were subjected to electron 
cryomicroscopy (Cryo-EM) (Fig 4.1) and helical image analysis. The image was 
reconstructed at 7.7 Å resolution as determined by the Fourier shell correlation 
(FSC) method at FSC = 0.143.   
 
Figure 4.1 DNGR-1 decorated actin filaments 
In vitro polymerized actin filaments were decorated with DNGR-1 ECD and 
subjected to electron cryomicroscopy. Image courtesy of T. Fujii and K. Namba. 
 
An electron density corresponding to DNGR-1 CTLD was observed binding into the 
groove between two actin protofilaments, making contacts with three actin subunits 
– two across the filament as well as two along one of the protofilaments (Fig 4.2A 
and B). Specificity for such composite site clearly explains the selective binding of 
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DNGR-1 exclusively to F-actin, with no detectable binding to monomeric G-actin. 
We could not observe any electron density corresponding to the neck region of 
DNGR-1, consistent with its flexibility, which will discussed in more detail in the 
following chapter (Fig 4.2A). 
 
Figure 4.2 Helical image analysis of cryoelectron micrographs of DNGR-1 
decorated actin filaments 
A, Helical image analysis of DNGR-1 decorated actin filaments showed electron 
density corresponding to DNGR-1 CTLD (in blue) bound in the groove between two 
actin protofilaments, making contact with three actin subunits in all. No density 
corresponding to the DNGR-1 neck region could be observed. B, Schematic 
depiction of the interacting molecules as shown in panel A. Images courtesy of 
T. Fujii and K. Namba. 
 
Previously published structures of hDNGR-1 CTLD (PDB ID 3VPP) (Zhang et al., 
2012) and F-actin (PDB ID 3MFP) (Fujii et al., 2010) could be fitted into the 
observed electron densities and FlexEM program (Topf et al., 2008) was used to 
build an atomic model of the complex (Fig 4.3). 
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Figure 4.3 Structure of DNGR-1 F-actin complex 
View of DNGR-1 and F-actin structures fitted into the electron density map. 
DNGR-1 is in rainbow colouring, G-actin subunits are coloured in orange, magenta 
and cyan, and their positioning corresponds to that in Fig 4.2 B. Images courtesy of 
T. Fujii and K. Namba. 
 
4.2.2 Electron cryomicroscopy identifies a loop absent in the crystal 
structure of DNGR-1 CTLD 
The structure of hDNGR-1 (Zhang et al., 2012) that was used to fit into the 
observed electron density map lacks five amino acids (R203 – A207), which 
presumably form a flexible loop. Unfilled electron density corresponding to this loop 
was observed in the electron density map of DNGR-1, suggesting that binding to 
F-actin results in folding and stabilization of the loop. To complete the model of 
DNGR-1 bound to F-actin (Fig 4.3) the missing residues (R226 – A230 in 
mDNGR-1) were modelled into the unfilled electron density (Fig 4.4). 
 
Figure 4.4 Flexible loop in DNGR-1 is stabilised by binding to F-actin 
Overlay of the published crystal structure of hDNGR-1 (blue) and model of 
mDNGR-1 (magenta) including the flexible loop (indicated with the arrow) fitted into 
the electron density map. Images courtesy of T. Fujii and K. Namba 
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4.2.3 Identification of the residues involved in the interaction of DNGR-1 
with F-actin 
While the resolution of the Cryo-EM electron density map was sufficient for 
unambiguous fitting of both DNGR-1 and F-actin structures, the side-chains of 
amino acids were not resolved. Consequently, only surfaces putatively involved in 
the interaction with the three actin subunits could be identified. Importantly, the 
surface putatively involved in the interaction with actin subunit 2 includes W155 and 
W250, residues corresponding to W131 and W227 in hDNGR-1, which were 
previously suggested to play a role in the interaction (Zhang et al., 2012). In all, 
sixteen residues, thirteen of which are conserved between mouse and human were 
identified in the putative interaction surfaces (Table 5). 
 
human 
DNGR-1 
mouse 
DNGR-1 
residue 
conserved 
interacting actin 
subunit 
N115 H139 no 1 
N116 N140 yes 1 
W117 W141 yes 1 
Y126 Y150 yes 1 
E129 E153 yes 1 
W131 W155 yes 2 
K143 K167 yes 1 
E144 E168 yes 1 
R165 G188 no 3 
K166 K189 yes 3 
K168 K191 yes 3 
D172 K195 no 2 
K215 K238 yes 2 
D225 D248 yes 2 
W227 W250 yes 2 
K228 K251 yes 2 
Table 5 Residues putatively involved in the interaction between DNGR-1 and 
F-actin 
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In order to address the contribution of the surfaces and residues putatively 
implicated in the interaction, we carried out mutational analysis of DNGR-1 ECD. 
We mutated each of the residues present in the identified surfaces as well as the 
residues forming the flexible loop, and expressed the mutants recombinantly as 
soluble FLAG-tagged proteins in 293F cells. All of the ECD mutants got expressed 
and secreted into the medium, albeit with different efficiency (Fig 4.5). We used 
densitometric analysis of Western blots to equilibrate the concentrations between 
the mutants and used the resulting supernatants at equal protein concentrations in 
a dot blot assay (Ahrens et al., 2012) (Fig 4.6) to assess their binding ability to 
F-actin. Decreasing amounts of in vitro polymerised actin were spotted onto a 
membrane, and the membrane was blocked and incubated with DNGR-1 ECD 
mutant supernatants and Dectin-1 ECD supernatant as a negative control. Binding 
of DNGR-1 was then revealed using anti-FLAG antibody. Consistently with the 
previous report (Zhang et al., 2012), W155A W250A double mutant failed to bind to 
F-actin. Mutating W250 alone also resulted in a complete loss of binding, while 
mutating W155 resulted in a significant decrease in binding. Both of these residues 
are involved in the interaction with actin subunit 2. Of the other residues putatively 
involved in the interaction with the same subunit, mutating K251 also resulted in a 
significant decrease in binding, while K238A mutant exhibited only mild phenotype. 
None of the other mutants (K195A, D248A) showed any decrease in binding to F-
actin (Fig 4.6A). Collectively, these data suggest that W250, W155, K251 and to a 
smaller extent K238 are involved in the interaction of DNGR-1 with actin subunit 2. 
 
Figure 4.5 Expression efficiency of DNGR-1 mutants 
Expression efficiency of all DNGR-1 mutants in 293F cells relative to WT protein. 
Data pooled from 5 different experiments. Bars represent mean ± s.d. 
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Of the residues putatively involved in the interaction with actin subunit 1, W141A 
mutant showed no binding and E153A mutant showed a significant decrease in 
binding. Of the other residues putatively involved in the interaction with the same 
actin subunit, mutating N140 and Y150 singly or doubly resulted in only minimal 
phenotype. No phenotype was observed when the other residues (H139, K167 and 
E168) were mutated (Fig 4.6A). Taken together, these data suggest that W141 and 
E153, and to a smaller extent N140 and Y150 residues are involved in the 
interaction with actin subunit 1. Both W141A and E153A mutants expressed poorly, 
suggesting the residues may play a role in the folding of the protein. Importantly 
though, both of the mutants were recognised by two different anti-DNGR-1 
antibodies (clone 7H11 and 1F6), suggesting the proteins were not grossly 
misfolded. Furthermore, W141 is oriented inwards in the crystal structure of 
hDNGR-1 CTLD, however, it is not part of the hydrophobic core of the protein, and 
is located on the hydrophilic side of the three-stranded β-sheet formed by the N- 
and C-terminal chains. Together with a density observed in the Cryo-EM data, this 
suggests that W141 may be able to flip out to interact with a hydrophobic patch on 
actin. 
Of the residues putatively involved in the interaction with actin subunit 3, 
only two are conserved between mouse and human (K189 and K191), and 
mutating them singly or doubly led to no detectable decrease in F-actin binding. 
The last residue (G188) was replaced with arginine in human DNGR-1. Substituting 
the glycine with arginine (G188R) in the context of mDNGR-1 led to a dramatic 
decrease in expression efficiency (Fig 4.5), however, the resulting protein appeared 
to bind to F-actin with increased efficiency (Fig 4.6A), suggesting a possible role for 
this residue. 
Interestingly, mutating the residues of the flexible loop, or replacing the whole loop 
with a string of 8 alanines (ΔLoop), resulted in no detectable decrease in binding 
(Fig 4.6B) despite the fact that the ΔLoop mutant showed drastic decrease in 
expression efficiency. (Fig 4.5) 
Collectively, these data suggest that only a handful of residues are crucial for the 
interaction of DNGR-1 with F-actin, and the interaction involves mostly actin 
subunits 1 and 2, while interaction with subunit 3 and the flexible loop appear to be 
dispensable for binding. 
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Figure 4.6 Identification of residues involved in the interaction of DNGR-1 with F-
actin 
Decreasing amounts of F-actin were spotted onto a nitrocellulose membrane and 
binding of indicated DNGR-1 mutants at equal concentration was tested. One 
representative experiment of three (upper panels) and quantitation relative to WT of 
three experiments (lower panels) are shown. Colour of the font and bars reflects 
the G-actin subunit that the residue is involved in interaction with, colours for the 
subunits are the same as in Figure 4.3. Bars represent mean ± s.d. *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001; One-way ANOVA with Dunnett’s multiple 
comparisons test. 
 
4.2.4 Binding of DNGR-1 to actin in dead cells is mediated by the same 
residues as to purified actin in vitro. 
In order to confirm that the observations we made using, in vitro polymerised 
F-actin are valid also for F-actin contained in dead cells, we utilised a flow 
cytometry (FACS) based assay. HeLa cells were UV-irradiated and left overnight to 
undergo secondary necrosis. Same protein supernatants as in the dot blot assay 
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were then used to stain the cell corpses. Using this assay, we observed a pattern 
of binding identical to that observed in the dot blot assay (Fig 4.7 A and B, compare 
with 4.6 A and B). The only difference was a seemingly lower binding of the G188R 
and ΔLoop mutant. This result could be an artefact caused by an overestimate of 
the abundance of low-expressing mutants in the densitometric analysis. While such 
overestimate does not pose problems for dot-blot analysis, because limited amount 
of ligand spotted on the membrane allows for saturation of binding, hence masking 
minor differences in concentration of different DNGR-1 mutants, reaching 
saturation may not be feasible for the much larger amount of actin present in dead 
cells, causing very low-expressing mutants to show apparently lower binding.  
 
Figure 4.7 Binding of DNGR-1 mutants to secondary necrotic HeLa cells 
HeLa cells were UV-irradiated and left to undergo secondary necrosis overnight. 
Following the incubation, the cell corpses were stained with WT and mutant 
DNGR-1 containing supernatants. Binding was assessed by flow cytometry with 
DAPI used to discriminate dead cells. One representative experiment of three is 
shown (upper panels). Binding index was calculated for each mutant and made 
relative to that of WT. Colour of the font and bars reflects the G-actin subunit that 
the residue is involved in interaction with, colours for the subunits are the same as 
in Figure 4.3. Results from three experiments were pooled and the bars represent 
mean ± s.d. P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; One-way ANOVA 
with Dunnett’s multiple comparisons test.   
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4.2.5 Pelleting assay confirms DNGR-1 mutant phenotypes 
Of the DNGR-1 mutants shown above, we selected those that expressed efficiently 
and showed different degree of F-actin binding – namely W155A W250A mutant as 
a non-binder, K251A mutant as a binder with significantly decreased affinity, and 
N140A Y150A as a binder with only minimal phenotype – and tested them in 
F-actin pelleting assay (Ahrens et al., 2012). Decreasing amount of DNGR-1 
proteins was incubated with constant amount of F-actin. Following the incubation, 
F-actin was pelleted, and both the pellet and supernatant were analysed by 
SDS-PAGE and Western blot for presence of DNGR-1. As expected, WT protein 
was largely found in the pellet. On the other hand, and consistently with the results 
of the dot blot assay, we observed no accumulation of the W155A W250A mutant 
in the pelleted material. Similarly, majority of the K251A mutant was also retained 
in the supernatant, confirming significant decrease of affinity of this mutant. On the 
contrary, N140A Y150A mutant was found predominantly in the pellet, consistent 
with its largely unchanged affinity for F-actin (Fig 4.8). 
 
 
Figure 4.8 Selected DNGR-1 mutants in pelleting assay 
Constant amount of F-actin was incubated with decreasing amount of indicated 
DNGR-1 proteins (decreasing protein concentration indicated by the wedge). The 
mixtures were ultracentrifuged and both pellet and supernatant were analysed 
using SDS-PAGE and Western blot. Data are representative of four experiments 
for WT and two experiments for each mutant. Colour of the font reflects the G-actin 
subunit that the residue is involved in interaction with, colours for the subunits are 
the same as in Figure 4.3. 
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4.2.6 Biolayer interferometry for F-actin binding proteins 
In order to obtain real-time binding data for DNGR-1 and F-actin interaction, we 
developed a method based on biolayer interferometry (BLI) (Abdiche et al., 2008). 
We mixed biotinylated and non-biotinylated actin (1:4) and allowed it to polymerise 
directly on a streptavidin-coated biosensor. F-actin polymerised in this way showed 
exceptional stability over prolonged periods of time (Fig 4.9), making it a suitable 
platform for testing binding of actin-binding proteins.  
 
 
Figure 4.9 F-actin polymerised on BLI biosensor is stable over prolonged periods 
of time 
Biotinylated and non-biotinylated actin preparations were mixed at 1:4 ratio, 
transferred into F-buffer, and allowed to polymerise directly on a 
streptavidin-coated biosensor (blue line). Same amount of biotinylated actin as 
present in the mixture was left in G-buffer and allowed to bind to the sensor (red 
line). Non-biotinylated actin at concentration equal to the final concentration of actin 
in the mixture was transferred into F-buffer, and allowed to polymerise in the 
presence of a streptavidin-coated biosensor (green line). After 2000 seconds of 
polymerisation, the sensors were moved to wells containing appropriate buffers, 
and dissociation phase was monitored for further 2000 seconds.  
 
To validate the assay, we first tested binding of α-actinin, a known actin-binding 
protein to the F-actin bound to the sensor. We observed specific binding of 
α-actinin in concentration dependent manner (Fig 4.10A). Steady state analysis of 
the binding curves from two experiments revealed Kd = 0.15 ± 0.04 µM (Fig 4.10B). 
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This result is in good agreement with results obtained using different methods and 
published previously (Wachsstock et al., 1993). 
 
 
Figure 4.10 Validation of biolayer interferometry setup for F-actin binding 
proteins 
A, Mixture of biotinylated and non-biotinylated actin was allowed to polymerise 
directly on a streptavidin-coated sensor and binding of α-actinin at the indicated 
concentrations was tested. Black lines denote mathematically fitted curves. One 
representative experiment of two is shown. B, Steady state analysis of α-actinin 
binding. Data are pooled from two independent experiments and represent mean ± 
s.d.  
 
4.2.7 DNGR-1 interaction with F-actin shows rapid kinetics but only modest 
affinity 
In order to explore binding of DNGR-1 to F-actin in more detail, we utilised the BLI 
setup that we developed and tested for α-actinin. In case of DNGR-1, we also 
observed a specific binding in concentration-dependent manner, however, dynamic 
analysis showed rapid kinetics of both association and dissociation 
(1.5×106 ± 4.2×105 M-1s-1 and 8.48×10-1 ± 9.6×10-2 s-1 respectively) (Fig 4.11A), and 
suggested a Kd in low micromolar range. Steady state analysis of the binding 
curves from seven independent experiments then showed Kd = 1.6 ± 0.3 µM (Fig 
4.11B), well within the range predicted previously by pelleting assay (Ahrens et al., 
2012). 
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Figure 4.11 DNGR-1 binds F-actin with rapid kinetics but only modest affinity 
A, Mixture of biotinylated and non-biotinylated actin was allowed to polymerise 
directly on a streptavidin-coated sensor, and binding of DNGR-1 at the indicated 
concentrations was tested. Black lines denote mathematically fitted curves. One 
representative experiment of seven is shown. B, Steady state analysis of DNGR-1 
binding. Data are pooled from seven independent experiments and represent mean 
± s.d.  
 
4.2.8 Biolayer interferometry confirms DNGR-1 mutant phenotypes 
To confirm the phenotypes of DNGR-1 mutants we observed in dot blot and 
pelleting assay, we tested the previously selected mutants in the biolayer 
interferometry setup. Consistently with what we observed using the other 
techniques, W155A W250A mutant showed no binding in our BLI setup, suggesting 
Kd > 100 µM (Fig 4.12A). For the K251A mutant we observed only weak signs of 
binding at the highest concentration used, suggesting Kd > 50 µM (Fig 4.12B). 
Finally, for the N140A Y150A mutant we observed only minimal decrease in affinity 
for F-actin (Kd = 2.7 ± 1.1 µM; Fig 4.12C). Thus, the results of all the biochemical 
assays are concordant and confirm the relative contribution of DNGR-1 residues to 
F-actin binding suggested by the dot blot screen of alanine mutants. 
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Figure 4.12 DNGR-1 mutants in biolayer interferometry 
Mixture of biotinylated and non-biotinylated actin was allowed to polymerise directly 
on a streptavidin-coated biosensor and binding of (A) W155A W250A, (B) K251, 
and (C) N140A Y150A DNGR-1 mutants at the indicated concentrations was tested 
(left panels). One representative experiment of three for N140A Y150A or two for 
the other mutants is shown. Black lines denote mathematically fitted curves. Steady 
state analysis (right panels) was performed on pooled data from all experiments 
and the data points represent mean ± s.d. Numbers represent best-fit curve values 
± standard error. 
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4.2.9 The dimeric status of DNGR-1 is essential for its efficient binding to 
F-actin 
DNGR-1 is constitutively expressed as a disulphide-bonded homodimer. This 
suggests that the affinity we determined for the DNGR-1 : F-actin interaction has a 
component of cooperativity, where binding of one part of the dimer potentiates 
binding of the other half. To assess to what extent is the dimeric status of DNGR-1 
important for efficient F-actin binding, we compared the binding of dimeric ECD 
protein with that of monomeric CTLD in the BLI assay. While the dimeric DNGR-1 
ECD showed clear binding to F-actin (Fig 4.13A and 4.11), in the case of the 
monomeric CTLD we saw no observable binding at the same concentrations, 
indicating Kd > 100 µM (Fig 4.13B). Taken together these results show that the 
dimeric status of DNGR-1 is essential for efficient recognition of F-actin and 
dramatically increases the strength of binding. 
 
 
Figure 4.13 Dimeric status of DNGR-1 enhances its ligand binding ability 
Mixture of biotinylated and non-biotinylated actin was allowed to polymerise directly 
on a streptavidin-coated biosensor, and binding of A, DNGR-1 ECD and B, CTLD 
at indicated concentrations was tested. One representative of seven experiments is 
shown for ECD and one representative of two experiments is shown for CTLD. 
 
4.2.10 Avidity component of the multivalent DNGR-1 : F-actin interaction 
dramatically increases the strength of binding in vitro 
A single actin filament has many DNGR-1 binding sites along its length, making it a 
polyvalent ligand. The way our BLI experiments were carried out, however, the 
polyvalency did not come into play, as DNGR-1 molecules were in solution, and 
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free to diffuse. This allowed DNGR-1 to associate and dissociate at a very fast rate, 
as shown in Fig 4.11, but it does not reflect the physiological reality of the 
interaction. Under physiological settings DNGR-1 is anchored into the cell 
membrane, restricting the interaction to only two dimensions. Thus, when an actin 
filament binds to DNGR-1 on the cell surface, it gets in close proximity of other 
DNGR-1 molecules, increasing the chance of interaction. Furthermore, once the 
filament is bound to multiple DNGR-1 molecules in the membrane and one of them 
dissociates, the filament remains bound by the remaining DNGR-1 molecules, and 
will also remain in close proximity of the dissociated molecule, making the chance 
of re-association higher, effectively decreasing the off-rate by means of avidity 
contribution (Fig 4.14).  
 
Figure 4.14 Schematic depiction of the involvement of avidity in the interaction 
between DNGR-1 and F-actin 
A, When F-actin is immobilised on a surface (such as the BLI sensor), molecules of 
DNGR-1 are free to diffuse upon dissociation, and avidity does not come into play. 
B, When in the context of a cell, DNGR-1 is anchored in the membrane, restricting 
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the interaction to two dimensions and allowing contribution of avidity to the overall 
strength of binding. 
 
In order to test to what extent avidity plays a role in DNGR-1 : F-actin interaction, 
we employed an inverted BLI setup. We immobilised DNGR-1 ECD on the surface 
of anti-FLAG biosensors, and tested binding of actin filaments. The number of 
concentrations at which binding of F-actin could be tested was severely limited due 
to the fact that F-actin spontaneously depolymerizes under the critical 
concentration of 0.6 µM (Pollard, 1986), and filaments at concentrations above 
2 µM caused significant artefacts in the BLI signal due to large filament size. In 
order to get around this limitation, we polymerized actin filaments in the presence 
of gelsolin (1000 : 1 ratio) to obtain shorter, capped filaments, and we tested 
binding at 1 µM F-actin. Under these conditions we observed a fast on-rate 
(7.6×103 ± 1.0×103 M-1s-1), but in contrast to what we observed when DNGR-1 was 
in solution and F-actin on the biosensor, the dissociation exhibited an extremely 
slow kinetics (6.4×10-5 ± 7×10-6 s-1) (Fig 4.15). These constants translate into a Kd 
= 8.7 ± 1.8 nM, suggesting that the avidity can increase the strength of binding by 
as much as three orders of magnitude. Notably, the extent of avidity contribution is 
directly dependent on the length of the filaments, and consequently the number we 
derived here is likely an underestimation, as the filaments were kept deliberately 
short in our experimental setup. 
 
Figure 4.15 Avidity increases strength of DNGR-1 : F-actin interaction 
DNGR-1 ECD was bound to anti-FLAG biosensor, and binding of 1 µM F-actin was 
tested. The curve is representative of six experiments, and the numbers represent 
the mean ± s.d. of all experiments.  
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4.2.11 Avidity in DNGR-1 internalization 
In vitro experiments suggested that avidity plays an important role in F-actin 
recognition by DNGR-1. To assess if this is also the case in the context of 
full-length, transmembrane DNGR-1, we retrovirally introduced WT or W141A, 
E153A, W155A W250A, W250A, K251A or N140A Y150A mutant DNGR-1 into 
Phoenix cell line, and tested how the mutants respond to antibody and F-actin 
cross-linking. As expected (Huysamen et al., 2008, Sancho et al., 2008), when 
treated with anti-DNGR-1 antibody, all of the mutants got internalised (Fig 4.16 and 
4.17), suggesting that they are not grossly misfolded, or otherwise unable to enter 
the endocytic pathway. On the contrary, when treated with F-actin, the mutants, 
which showed complete loss of binding in our biochemical assays (W250A, W155A 
W250A and W141A) also showed complete block of internalization (Fig 4.16 and 
4.17). Surprisingly though, the mutants which showed strong defect in binding 
(K251A, E153A) still got internalised, albeit to smaller extent than the WT (Fig 4.16 
and 4.17). Consistently with its largely unaffected affinity for F-actin, N140A Y150A 
mutant was indistinguishable from WT in its ability to internalise (Fig 4.16 and 4.17). 
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Figure 4.16 All DNGR-1 mutants are capable of being internalized 
Phoenix cells expressing indicated mutant or WT DNGR-1 proteins were treated 
with F-actin, F-buffer, anti-DNGR-1 antibody or isotype-matched antibody of 
irrelevant specificity for 60 minutes at 37°C, fixed in formaldehyde, surface-stained 
for DNGR-1 and analysed by flow cytometry. One representative of six experiments 
is shown. 
 
Chapter 4 Results 
 
109 
 
 
Figure 4.17 Avidity can compensate for a decrease in affinity in DNGR-1 
internalization assay 
Data from six independent experiments as in Fig 4.16 were normalized to the 
antibody-induced internalization and made relative to internalization of the WT. The 
bars depict mean ± s.d. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; 
One-way ANOVA with Dunnett’s multiple comparisons test. 
 
4.2.12 Avidity in DNGR-1 signalling assay 
In order to assess whether our observations in the internalization assay are also 
valid in DNGR-1 signalling assay, we utilized B3Z-Syk reporter cell line, where 
Syk-mediated NFAT activation results in transcription of β-galactosidase (Sancho 
et al., 2009). Syk activation can thus be read out using a chromogenic 
β-galactosidase substrate (CPRG). We stimulated reporter cells expressing WT or 
W155A W250A, K251A, E153A or N140A Y150A mutants with secondary necrotic 
cells at different ratios and assessed Syk activation. To account for differential 
expression of various mutants, we normalised the dead cell-induced response to 
response induced by plate-bound anti-DNGR-1 antibody. As expected, all the cells 
responded to antibody stimulation, and WT DNGR-1 allowed the cells to respond to 
dead cells. Consistently with what we saw in the internalization assay, the W155A 
W250A mutant showed no response to dead cells, while all the other mutants 
responded to extent comparable to WT, with only E153A mutant showing a mild 
decrease in response (Fig 4.18). Taken together, the data from internalization and 
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B3Z-Syk reporter assays suggest that the avidity component plays a significant role 
in F-actin recognition by transmembrane DNGR-1, and in both cases can 
compensate even for a significant decrease in affinity. 
 
Figure 4.18 DNGR-1 mediated activation of reporter cells in response to dead-cell 
stimulation 
B3Z-Syk reporter cells overexpressing mutant or WT DNGR-1 were incubated 
overnight with secondary necrotic cells at indicated ratios. Syk-mediated 
NFAT-activation was read out following the incubation. To account for different 
surface expression of different mutants, the response was made relative to the 
response induced by plate-bound anti-DNGR-1 antibody. The bars represent mean 
± s.d. of three independent experiments.  
 
4.2.13 DNGR-1-mediated cross-presentation 
Cross-presentation of dead cell-associated antigens was previously shown to be 
DNGR-1 dependent (Iborra et al., 2012, Sancho et al., 2009, Zelenay et al., 2012). 
In order to confirm a requirement for F-actin recognition in DNGR-1 function, and to 
assess the effects of decrease in affinity on DNGR-1 mediated cross-presentation, 
we established collaboration with David Sancho and Salvador Iborra (Centro 
Nacional de Investigaciones Cardiovasculares, Madrid, Spain). Dendritic cells 
obtained by culture of bone marrow from DNGR-1 knock out (KO) mice in medium 
containing Flt3 ligand were transduced with empty retrovirus as a control or 
retroviruses encoding for WT, W155A W250A and K251A DNGR-1. Transduced 
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cells were then incubated at different ratios with Vaccinia-OVA-infected RAW264.7 
cells, which were or were not UV-irradiated, and the capacity of DCs to present 
viral antigen to antigen-specific CD8+ T-lymphocytes was assessed by determining 
the proportion IFN-γ+ T-cells after the coculture (Iborra et al., 2012). Under 
conditions where direct antigen presentation was allowed (non-irradiated virus), all 
DCs presented equally efficiently, confirming no impairment in the process of 
antigen presentation per se (Fig 4.19, left). Consistently with previously published 
data, when the virus was UV-irradiated and cross-presentation was the only route 
of antigen presentation, the DNGR-1 KO cells transduced with the control virus 
showed a significant impairment in T-cell priming compared to WT cells (Fig 4.19, 
right) (Iborra et al., 2012). As expected, reintroduction of WT DNGR-1 into KO cells 
rescued their cross-presentation capability, while the W155A W250A mutant failed 
to do so (Fig 4.19, right), formally demonstrating that F-actin recognition is 
essential for DNGR-1 function. Surprisingly, and in contrast with the results 
obtained with B3Z-Syk reporter cells, the DCs transduced with K251A mutant 
DNGR-1 showed only an intermediate phenotype (Fig 4.19, right). Whether this 
result is due to different surface density of DNGR-1, expression levels of Syk, or 
different extent of cross-linking required for productive signalling in the different cell 
types is unclear.  
 
Figure 4.19 F-actin recognition is essential for DNGR-1 mediated 
cross-presentation of dead cell-associated antigens 
Raw264.7 cells were infected with Vaccinia OVA virus and UV-irradiated 
(RAW-VACV-UV) or left un-irradiated (RAW-VACV) and plated at indicated ratios 
with dendritic cells and ovalbumin specific T-lymphocytes. Production of IFNγ by 
T-lymphocytes was read out after 6 hours of stimulation and percentage of IFNγ+ 
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cells within the CD8+ population was determined. One representative of three 
experiments is shown. Image courtesy of S. Iborra and D. Sancho. 
 
4.3 Discussion 
DNGR-1 is the only known transmembrane protein recognizing F-actin in the 
extracellular environment, and at the same time the only known C-type lectin to 
bind this polymeric ligand. As such it is of clear interest to understand the 
mechanism of binding at atomic level. Here we present the structure of actin 
filament decorated with DNGR-1 at 7.7 Å resolution with a list of residues involved 
in the interaction validated by mutational analysis. We define a flexible loop missing 
in the crystal structure of DNGR-1, determine the contribution of avidity to the 
interaction, and formally demonstrate the requirement of ligand recognition for 
DNGR-1 function in dendritic cells.  
Interestingly, DNGR-1 binds into the groove between two actin protofilaments, 
making contacts with two actin subunits across the filament and at the same time 
with two actin subunits along one protofilament. This mode of binding is very 
uncommon among canonical actin-binding proteins, although it shares some 
features with that of coronin (Galkin et al., 2008, Ge et al., 2014), Arp2/3 complex 
(Rouiller et al., 2008) and Salmonella SipA protein (Lilic et al., 2003). Binding site of 
DNGR-1, however, shows only partial overlap with binding sites of any of the above 
proteins, and is characterized by a surprisingly small interface with only a handful 
of residues contributing to the interaction. This suggests that DNGR-1 has 
specifically evolved to bind to F-actin regardless of its decoration with most other 
actin-binding proteins, even though proteins that affect conformational state of actin 
are still likely to interfere with DNGR-1 binding. In fact cofilin, an actin binding 
protein, which changes the helical twist of actin filaments (McGough et al., 1997), 
has been shown to block DNGR-1 binding to F-actin (Zhang et al., 2012). 
In agreement with the small interaction interface, DNGR-1 shows only a modest 
affinity for F-actin, together with a very rapid kinetics of association and dissociation. 
This appears counterintuitive for a receptor that recognizes a ligand that is scarce 
in the extracellular milieu. However, the polymeric state of F-actin suggests that an 
avidity component is likely to come into play when DNGR-1 is bound in the 
membrane. Indeed, we demonstrate that when DNGR-1 is bound to a surface, the 
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strength of binding increases by as much as three orders of magnitude, and the 
avidity can even compensate for a decrease in affinity, explaining how the 
evolutionary trade-off between high affinity large binding site, which could be 
obscured by other actin-binding proteins, and a low-affinity small one, binding to 
which, however, is unlikely to be hindered by other proteins, can work in favour of 
the latter.   
Finally, DNGR-1 was previously shown to play a role in cross-presentation of dead 
cell-associated antigens, which was dependent upon its ability to elicit productive 
signalling through the intracellular hemITAM motif (Sancho et al., 2009). The 
evidence for direct F-actin involvement in this process, however, has to date been 
largely indirect. Here we show that DNGR-1 incapable of F-actin recognition does 
not induce Syk-mediated signalling in reporter cell line when exposed to dead cells, 
and importantly, we formally demonstrate that the ability to recognize F-actin is 
essential for the function of DNGR-1 in DCs, as mutant incapable of F-actin binding 
is also incapable of rescuing the cross-presentation defect in DNGR-1-deficient 
DCs. 
Notably, some of the actin residues present in close proximity to DNGR-1 binding 
site can undergo posttranslational modifications including phosphorylation, nitration 
and ubiquitination (Terman and Kashina, 2013). The physiological function of 
majority of these currently remains enigmatic (Terman and Kashina, 2013), it is, 
however, tempting to speculate that some of the modifications could serve as a 
readout of the cellular state and/or modality of cell death, and by means of affecting 
DNGR-1 binding they could help regulate the immune response to dead 
cell-associated antigens. 
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Chapter 5. DNGR-1 can bind with both 
ligand-binding domains to the same actin filament 
5.1 Introduction 
Even though our structure of DNGR-1 : F-actin complex allows detailed 
understanding of the interaction at the level of single ligand-binding domains, the 
exact spatial organisation of DNGR-1 molecules along the filament remains 
unknown. It has been suggested previously that DNGR-1 is likely able to bind in 
trans, crosslinking two actin filaments within an F-actin bundle (Ahrens et al., 2012), 
however, whether binding in cis to a single filament with both ligand-binding 
domains is also possible remains to be established. Consequently, in order to gain 
insight into the mode of DNGR-1 binding, we decided to set up a system in which 
we could analyse binding to single actin filaments of a heterodimeric DNGR-1 ECD 
protein where one half of the dimer is WT and the other half bears the W155A 
W250A mutation. Such protein, even though dimeric, would behave as a monomer 
in terms of ligand binding. Consequently, if DNGR-1 can bind in cis, the homodimer 
should exhibit stronger binding to single actin filaments than the heterodimer, owing 
to the cooperativity between the two ligand-binding domains (Fig 5.1, left). On the 
other hand, if DNGR-1 can only bind in trans, the monomer and dimer should be 
indistinguishable in binding to single actin filaments, because the cooperativity can 
not come into play (Fig 5.1, right). Importantly, only binding to single actin filaments 
can distinguish between the two scenarios, as both ligand-binding domains can 
come into play in the interaction with bundled actin, as suggested by the difference 
in affinity we observed between the dimeric ECD and monomeric CTLD (Fig 4.13). 
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Figure 5.1 Schematic depiction of possible modes of DNGR-1 binding and their 
impact on the binding of the homo and heterodimeric proteins to single actin 
filaments 
If DNGR-1 can bind with both ligand-binding domains to a single actin filament 
(cis), the heterodimer would show decreased affinity for such filaments compared 
to the WT (left). If DNGR-1 can bind only in trans, crosslinking different filaments, 
the affinity of WT and heterodimer for single actin filaments would be identical 
(right).  
 
5.2 Results 
5.2.1 Generation of labelled heterodimeric DNGR-1 ECD proteins 
In order to generate heterodimeric DNGR-1 ECD, we co-transfected 293F cells 
with FLAG-tagged W155A W250A DNGR-1 and HA-tagged WT DNGR-1, or, as a 
control, FLAG-tagged WT and HA-tagged WT DNGR-1. All the proteins additionally 
possessed a short sequence of amino acids known as a “sortag” fused to their 
C-terminus, which allows covalent linkage to labelled peptides of specific sequence 
by means of enzymatic reaction with Sortase A (sortagging) (Popp et al., 2009). 
The advantage of such labelling, compared to a nonspecific one such as the 
amine-coupling chemistry, is that exactly one molecule of fluorophore will be 
Chapter 5. Results 
 
116 
 
attached to each DNGR-1 monomer. Furthermore, using this setup, the site of 
labelling is clearly defined and shared among all the molecules, minimising the 
likelihood of the label being randomly placed in a site where it could interfere with 
the DNGR-1 binding. Consequently, using sequential affinity purification on M2-
anti-FLAG affinity gel and anti-HA-agarose with the sortagging step in between (Fig 
5.2), we were able to obtain fluorescently labelled heterodimeric DNGR-1.  
 
 
Figure 5.2 Schematic depiction of the workflow for generation of heterodimeric 
DNGR-1 ECD 
Transient co-transfection of DNA coding for differently tagged WT and W155A 
W250A DNGR-1 ECD into 293F cells results in the production of a mixture of homo 
and heterodimeric proteins. The heterodimers can subsequently be purified by two 
sequential affinity purification steps. Fluorescent label is introduced by the 
sortagging reaction in between the affinity purification steps.  
 
5.2.2 Validation of fluorescently labelled DNGR-1 proteins 
In order to validate the fluorescently labelled DNGR-1 proteins, we tested their 
ability to bind to dead cells. We UV-irradiated HeLa cells, let them undergo 
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secondary necrosis overnight and stained the cell corpses on the following day 
directly with labelled WT : WT homodimer or WT : W250A W155A heterodimer. As 
a control, staining with unlabelled FLAG-tagged ECD (dimeric) and CTLD 
(monomeric) was also tested, and their binding was revealed using an anti-FLAG 
antibody. In both cases, the extent of binding was assessed using flow cytometry 
with DAPI used to discriminate dead cells. As expected, the WT : WT homodimer 
bound more strongly to dead cells than the WT : W155A W250A heterodimer (Fig 
5.3A), suggesting an increase in the affinity of the homodimer compared to the 
heterodimer, due to cooperativity between the two ligand-binding domains. 
Encouragingly, when we compared the dimeric ECD with monomeric CTLD in the 
same assay, detecting DNGR-1 binding to dead cells with an anti-FLAG antibody, 
we observed an identical pattern where dimeric ECD bound more strongly than 
monomeric CTLD (Fig 5.3B). The F-actin present in dead cells is mostly in the form 
of actin bundles (Furukawa and Fechheimer, 1997, Claessens et al., 2006). 
Consequently, these results cannot give us any insight into the ability of DNGR-1 to 
bind to single actin filaments, but rather they demonstrate the ability of DNGR-1 to 
utilise both of its ligand-binding domains when interacting with bundles of F-actin, 
as suggested previously (Ahrens et al., 2012). 
 
 
Figure 5.3 Binding of homo and heterodimeric DNGR-1 to dead cells 
HeLa cells were UV-irradiated and left to undergo secondary necrosis overnight. 
Following the incubation, the cell corpses were stained with indicated DNGR-1 
proteins and their binding was assessed using flow cytometry. Dead cells were 
differentiated by staining with DAPI. A, Binding of labelled proteins was assessed 
directly using the fluorescent label B, binding of unlabelled ECD and CTLD was 
assessed using Cy-3 anti-FLAG antibody. 
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5.2.3 Binding of heterodimeric DNGR-1 proteins to single actin filaments 
Generating single actin filaments in vitro is complicated by the propensity of F-actin 
to form bundles. In order to circumvent this problem, we utilised a previously 
developed setup where spectrin was allowed to non-specifically adsorb onto a 
cover slip and the bound molecules were then used as seeds for F-actin 
polymerization (Jegou et al., 2011). This, together with short polymerization time 
(5 min), allowed us to obtain short single actin filaments anchored to the cover slip. 
The filaments were stained by fluorescently labelled phalloidin, decorated with the 
labelled homo or heterodimeric DNGR-1 proteins, and imaged using TIRF 
microscopy. While we observed clear binding of WT : WT protein, we could not 
detect any stable binding of the heterodimeric W155A W250A : WT protein (Fig 
5.4), suggesting that WT DNGR-1 can bind to single actin filaments with both of its 
ligand-binding domains. Unexpectedly, for the WT : WT protein, we did not see 
uniform actin decoration, but rather a patchy staining reminiscent to that of cofilin 
(McGough et al., 1997). This mode of binding would suggest a previously 
unappreciated degree of cooperativity between DNGR-1 molecules. 
 
Figure 5.4 DNGR-1 homodimer and heterodimer binding to single actin filaments 
Actin filaments were polymerised on spectrin seeds adsorbed onto coverslip 
chambers to obtain single filaments and stained with phalloidin (red). Indicated 
labelled DNGR-1 proteins (green) were floated into the chamber and the coverslips 
were imaged using TIRF microscope. 
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5.3 Discussion 
It has previously been argued that DNGR-1 is likely to be able to bind in trans, 
crosslinking pre-bundled actin filaments (Ahrens et al., 2012). Such notion is 
supported by an apparent increase in the strength of binding of DNGR-1 to F-actin 
when the latter is complexed with actin-binding proteins that can induce its bundling 
(Ahrens et al., 2012, Zhang et al., 2012). This line of evidence, however, is largely 
indirect, and the ability of DNGR-1 to bind in trans is difficult to prove formally. 
Consequently, in this study, we set out to assess if DNGR-1 is able to bind in cis. 
Using heterodimeric constructs, we demonstrate that WT DNGR-1 ECD has higher 
affinity for single actin filaments than DNGR-1 ECD molecules in which one part of 
the dimer has been substituted with a mutant incapable of binding to F-actin. Such 
protein has all the biophysical properties of WT DNGR-1, but its ligand-binding 
ability corresponds to that of a monomer. Consequently, taken at face value, our 
data suggest that both ligand-binding domains of one DNGR-1 molecule can bind 
to binding sites on a single actin filament in cis. Importantly, this observation does 
not mean that DNGR-1 could not bind in trans. The apparent ability of DNGR-1 to 
bind in cis, however, brings about a conceptual problem of how can both 
ligand-binding domains reach their binding sites. The binding sites for DNGR-1 on 
an actin filament are separated by around 6 nm, generating a repetitive pattern with 
largely translational symmetry (Fig 5.5A). The two neighbouring CTLDs bound to 
the filament share no interface, have about 2 nm of free space between them, and 
are both oriented in the same way, also exhibiting largely translational symmetry 
(Fig 5.5A). On the other hand, the symmetry that one would expect between the 
two parts of unbound DNGR-1 dimer is rotational, as suggested by the LOX-1-like 
DNGR-1 dimer model (Zhang et al., 2012) (Fig 5.5B) and seen in other C-type 
lectin receptors (Back et al., 2009, Park et al., 2005). The only way to reconcile 
these contradictory properties is to assume that there, in fact, is no rigid 
dimerization interface, and that the two CTLDs can exist and bind independently. 
Additionally, the neck region and the hinge between the neck and the CTLD have 
to be flexible enough for the two CTLDs to be able to twist in such a way that the 
rotational symmetry of unbound protein can change into a translational one upon 
binding to a single actin filament. Since the extra exon present in the long isoform 
of murine DNGR-1 lies in between the dimerizing cysteine and the CTLD, and 
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based on the structure prediction as well as our CD data appears to be largely 
unstructured, it is tempting to speculate that the long isoform of mouse DNGR-1 
has evolved to give the CTLDs more flexibility than would be the case for the short 
isoform. How would such difference reflect on the functional properties of the 
receptors, however, is not clear, as under in vivo settings F-actin rarely appears in 
the form of single filaments, obviating the need for the ability to bind in cis.  
Intuitively, even for the interaction in trans, DNGR-1 needs to be flexible enough to 
“reach” the two actin filaments, although, conceivably, the degree of flexibility 
required for such mode of interaction could be lower. Consistently, reporter cells 
expressing long or short murine DNGR-1 are activated by dead cells to similar 
extent (data not shown), and in human there is no homologue of the long isoform 
altogether, suggesting that the evolutionary pressure on higher mobility of DNGR-1 
CTLDs may be limited. It would be interesting to repeat the TIRF experiment with 
the short mouse or human DNGR-1 isoforms, or mutants lacking parts of the neck 
region between the dimerizing cysteine and the CTLD to see if decreased mobility 
and/or flexibility of the neck would result in impaired binding of DNGR-1 to single 
actin filaments.  
In summary, our data demonstrate that DNGR-1 can bind in cis to single actin 
filaments, but this is not to say that this mode of recognition is necessarily utilised 
in vivo. Importantly, however, what our data show is that even though DNGR-1 is 
constitutively dimeric, there appears to be no dimerization interface between the 
two CTLDs, and they can exist and bind independently. 
   
 
Figure 5.5 – Incompatibility between the mode of DNGR-1 binding and the 
LOX-1-like model of DNGR-1 dimerization 
A, Crystal structure of DNGR-1 CTLD (PDB ID 3VPP; light blue)(Zhang et al., 
2012) was fitted into electron density of DNGR-1-decorated actin filament as in 
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Fig 4.3. The distance between corresponding atoms of the two DNGR-1 CTLDs 
was determined in the UCSF Chimera software (black dashed line). B, Crystal 
structure of DNGR-1 CTLD (PDB ID 3VPP; (Zhang et al., 2012)) was aligned with 
both chains of the LOX-1 dimer (PDB ID 1YPU)(Park et al., 2005) using the 
MatchMaker tool in the UCSF Chimera software. RSMD for both chains was below 
1 Å. DNGR-1 CTLD in light blue, LOX-1 in green. 
 
Finally, the patchy staining pattern we observed for DNGR-1 on single actin 
filaments indicates a surprising cooperativity in binding between DNGR-1 
molecules. Our Cryo-EM data rule out the possibility that DNGR-1, like cofilin, 
induces a large change in filament helicity, however, small changes that could get 
propagated along the filament cannot be ruled out at the resolution we achieved. 
Given the polymeric form of F-actin, with the binding sites appearing in regular 
intervals, it is conceivable that binding to F-actin positions the DNGR-1 molecules 
on the cell surface in the right distance from each other to induce signalling. If this 
were to be the case, a cooperative mode of binding, whereby occupation of one 
binding site potentiates binding of a second DNGR-1 molecule to the neighbouring 
one would be of clear advantage, allowing a “clustered” positioning of DNGR-1 
molecules around one spot, rather than random distribution along the filament. As 
the binding sites are positioned in a helical pattern relative to one another, this 
would also be another reason why flexibility of DNGR-1 would be of importance, 
making it possible for DNGR-1 molecules to reach their binding sites on a filament 
even if those happen to be positioned in a way that they are not facing directly 
downwards towards the cell membrane. 
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Chapter 6. Final discussion 
The field of DAMP recognition has rapidly expanded over the last years, with 
various endogenous molecules ranging from heat shock proteins (Asea et al., 
2000) to uric acid crystals (Martinon et al., 2006, Neumann et al., 2014) now being 
widely accepted as putative DAMPs. Lack of detailed understanding of these 
interactions at molecular level has, however, hampered the advancement of the 
field and resulted in controversies over specificity of some of these interactions 
(Bausinger et al., 2002).  
Currently the only way to confirm the specificity of any interaction observed within a 
biological system beyond any reasonable doubt is to take a step back from 
complex in vivo systems and assess the interaction and properties of all the 
putative interaction partners under simplified in vitro settings where purified 
reagents can be used, minimizing or completely avoiding interference from other 
players that might appear in vivo. Similarly, in order to provide a description of a 
protein’s properties, one is best served by applying direct biophysical techniques to 
a purified protein or a defined mixture of those. Stemming from this rationale, in this 
work we attempted to provide a comprehensive description of the properties of a C-
type lectin receptor, DNGR-1, and its interaction with F-actin based on in vitro 
approaches, where possible drawing conclusions about functional aspects of the 
protein in its biological settings. 
Taken together, our structural data confirm the specificity of DNGR-1 for F-actin, 
unambiguously explain its exclusive binding to the polymeric form, and rule out the 
necessity of accessory proteins for the interaction. Additionally, we formally 
demonstrate the necessity of ligand-recognition for DNGR-1-mediated 
cross-presentation of dead cell-associated antigens by dendritic cells, and an 
important contribution of avidity to the interaction. Notably, we also show that 
DNGR-1 is able to bind with both of its ligand-binding domains to a single actin 
filament, demonstrating an unexpected degree of flexibility in the neck region as 
well as the absence of a rigid dimerization interface between the two DNGR-1 
CTLDs. Finally, we note that the neck region of DNGR-1 serves as a pH- and ionic 
strength-specific sensor, conceivably allowing DNGR-1 to discriminate between 
extracellular and endosomal environments by changing its conformational state, 
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and suggesting a way in which DNGR-1 might modulate its function based on its 
subcellular localization.  
Our study brings to light several questions: Firstly, do the cellular metabolism 
and/or infected state of a dying cell affect posttranslational modifications of actin or 
decoration of filaments with certain ABPs, thereby affecting DNGR-1 binding? 
Observations have been made for HMGB-1 where, depending on the redox state of 
its cysteines as well as its acetylation, different functional outcomes ensue after its 
extracellular recognition (Yang et al., 2013), suggesting that at least in some cases 
such mode of regulation of DAMP recognition has indeed evolved. Unfortunately, 
while a plethora of posttranslational modifications have been reported for actin, not 
much is known about their function or how are they regulated (Terman and Kashina, 
2013). On the other hand, ABPs and their function and influence on actin have 
been a focus of intensive research, and involvement of some ABPs, as well as the 
overall status of the actin cytoskeleton in the processes of cell death have been 
noted both in higher eukaryotes and in yeast (Desouza et al., 2012, Gourlay et al., 
2004). Of particular interest, cofilin, an ABP that changes helical twist of actin 
filaments and has been shown to interfere with DNGR-1 binding (Zhang et al., 
2012), plays a role in programmed cell death, and its mitochondrial translocation is 
an early step in both apoptosis and necroptosis induction (Chua et al., 2003, Karch 
et al., 2015). It is, consequently, tempting to speculate that cofilin translocation from 
the cytoplasm could improve F-actin-recognition by DNGR-1, thus making F-actin 
of dead-cell origin a better ligand, even though further work will be needed to 
address if this is indeed relevant for DNGR-1 binding to F-actin and its function. 
Second obvious question stemming from our data is, what is the advantage of 
DNGR-1 being able to bind with both of its ligand-binding domains to a single 
filament, given that under in vivo settings actin rarely, if ever, appears in this form? 
To consider this question, one first needs to take into account that, compared to 
other isoforms, the DNGR-1 isoform for which we observed such behaviour 
contains an extra stretch of twenty six amino acids between the CTLD and the 
dimerization cysteine, which is likely to make the flexibility of the protein even more 
pronounced. Consequently, it is reasonable to assume that the isoforms devoid of 
these extra amino acids would be less likely to exhibit the same ability, but this will 
need to be addressed experimentally. As a result, the answer may be that under in 
vivo settings there, in fact, is no need for DNGR-1 to be able to bind to single actin 
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filaments with both of its ligand-binding domains, and what we observed for the 
long DNGR-1 isoform is an isoform-specific property. Importantly, however, our 
observations provide a proof of principle, suggesting an absence of dimerization 
interface between the DNGR-1 CTLDs and their ability to exist independently, 
which are properties likely to be conserved between isoforms, regardless of the 
length of the neck region. And while the biological rationale for the ability of 
DNGR-1 to bind to single actin filaments in cis is unclear, the ability of the two 
domains to move and bind independently is of importance also for the ability of 
DNGR-1 to bind in trans. Most transmembrane receptors bind to ligands that have 
defined geometry, whether they are soluble molecules, other transmembrane 
proteins, or ligands arrayed in an orderly fashion on a surface. In stark contrast, 
DNGR-1 binds to F-actin, which in its bundled form is likely to have the DNGR-1 
binding sites distributed at, more or less, random intervals (although closer together 
than would be the case for a single filament), making it disadvantageous for 
DNGR-1 to be limited to a single geometry of recognition, which would be imposed 
by a rigid dimerization interface. Notably, the structural similarity of DNGR-1 and 
LOX-1 CTLDs (Zhang et al., 2012), together with the fact that the dimerization 
interface of LOX-1 hinges on the presence of a single amino acid (Nakano et al., 
2012), suggest an evolutionarily plausible way how such adaptation could have 
easily arisen. 
Thirdly, we observed an ability of DNGR-1 to undergo a conformational change in a 
pH- and ionic strength-specific manner. Similar behaviour has been described for 
other C-type lectin receptors, however, the biological function of the conformational 
change observed in these cases does not appear to be shared with DNGR-1, 
begging the question, what is its function, if any? Importantly, we observed the 
conformational change in multiple DNGR-1 isoforms, suggesting that it is not just 
an isoform-specific artefact. Furthermore, the amino acid composition of the neck 
region is no less conserved between species than that of the ligand-binding domain, 
suggesting that the evolutionary pressure on the two parts of the protein is similar. 
This would argue in favour of a model where the neck plays an important role in 
DNGR-1 biology, beyond its function as a mere scaffold upholding the CTLD and 
connecting it to the membrane. Intuitively, for DNGR-1, regulation of its function 
based on its subcellular localization makes sense – on the cell surface it needs to 
act as an endocytic receptor, mediating internalization of dead cell-associated 
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material, while in the endosomes it acts through an as-of-yet incompletely 
understood mechanism to prevent maturation of the endosomes. It would make 
little sense for DNGR-1 to signal for block in endosomal maturation from cell 
surface, much like to signal for internalization from inside a vesicle. How exactly is 
this “division of labour” achieved mechanistically remains to be conclusively shown, 
however, the conformational change we describe provides a way for DNGR-1 to 
“sense” its environment and also to react to it, making it a prime candidate for such 
mechanism (Fig 6.1).   
In summary, our study significantly broadens our knowledge of the biology and 
biochemistry of DNGR-1, but at the same time it alsoemphasises several new, 
previously unappreciated questions, answers to which will require further research. 
 
 
Figure 6.1 - Schematic model of how a conformational change in the neck can 
allow spatial regulation of DNGR-1 function 
Repositioning of the neck regions can result in repositioning of the intracellular 
signalling motifs, thereby affecting the ability of DNGR-1 to interact with various 
proteins
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